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ABSTRACT
THE ROLE OF SLC7A11 IN CONTROLLING EXTRACELLULAR AND
INTRACELLULAR REDOX ENVIRONMENTS OF LUNG FIBROBLASTS –
POTENTIAL TARGETS FOR INTERVENTION IN AGING AND IDIOPATHIC
PULMONARY FIBROSIS
Yuxuan Zheng
April 9, 2020
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by
extracellular matrix deposition by fibroblasts. Aging and oxidative stress
increase the susceptibility to IPF. Redox couples, cysteine/cystine (Cys/CySS)
and glutathione/glutathione disulfide (GSH/GSSG), and their redox potentials
(Eh) quantify oxidative stress. Fibroblasts from old mice maintain more oxidized
extracellular Eh(Cys/CySS) than young mice. Microarray shows downregulation of Slc7a11 potentially mediates this age-related oxidation. Slc7a11
is the key component of system Xc-, an antiporter that imports CySS and
exports glutamate. The first aim of this dissertation is to investigate the
mechanistic link between Slc7a11 expression and extracellular E h(Cys/CySS).
The second aim is to evaluate the effects of aging on the redox states of
intracellular proteins and whether Slc7a11 contributes to the age-dependent
effects. The last aim is to compare SLC7A11 expression, extracellular
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Eh(Cys/CySS) and intracellular Eh(GSH/GSSG) between human lung
fibroblasts from IPF and non-IPF donors and to explore their association with
pro-fibrotic gene expression.
Slc7a11 expression was manipulated by pharmacological and genetic
methods. Reduced and oxidized forms of Cys residues were labelled by
Iodoacetyl Tandem Mass Tags. The ratio of oxidized/reduced forms (i.e., redox
state) of a Cys residue was determined by multiplexed tandem mass
spectrometry.
Eh(Cys/CySS) and Eh(GSH/GSSG) were more oxidized in conditioned
media of old fibroblasts. Up-regulation of Slc7a11 reduced extracellular
Eh(Cys/CySS) for old fibroblasts. Inhibition of GSH synthesis had no effect on
the ability of cells to restore their extracellular Eh(Cys/CySS). Redox states of
151 proteins changed with aging. Slc7a11 over-expression restored redox
states of 104 proteins. Ingenuity Pathway Analysis showed these 104 proteins
were involved in pathways of protein translation initiation, ubiquitinproteasome-mediated

degradation

and

integrin-cytoskeleton-associated

signaling. Slc7a11 expression was lower in IPF fibroblasts. Extracellular
Eh(Cys/CySS) was more oxidized and expression of pro-fibrotic genes was
higher in IPF fibroblasts.
In conclusion, Slc7a11 is the key regulator of extracellular E h(Cys/CySS).
Its effects are independent of GSH synthesis. Aging results in changes of redox
states of proteins involved in protein turnover and cytoskeleton dynamics. Up-
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regulating Slc7a11 restores changes of protein redox states due to aging.
Decreased SLC7A11 might represent a susceptibility factor for developing
tissue disrepair and fibrosis in IPF.
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CHAPTER I

INTRODUCTION

1.1 Overview of idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is characterized by scarring of the lung
without known causes. Normally, the connective tissues between alveoli are
very thin so that oxygen can diffuse effectively. However, IPF is characterized
by irreversible destruction of alveoli and remodeling of lung with excessive
synthesis and deposition of extracellular matrix (ECM) in the interstitial spaces
(1). As the interstitium becomes thicken, the function of the lung for gas
exchange gradually declines. According to the American Thoracic Society (ATS)
guideline, IPF is defined as “a specific form of chronic, progressive fibrosing
interstitial pneumonia of unknown cause, occurring primarily in older adults,
limited to the lungs, and associated with histopathologic and/or radiologic
pattern of usual interstitial pneumonia (UIP)” (2).
Generally, the pathological pattern of IPF is UIP. Although not
pathognomonic, pathological UIP increases the confidence of IPF diagnosis if
radiological UIP pattern is suspected but not well established after patient
history is thoroughly reviewed and potential causes are excluded (3). Fibrosis
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in IPF is primarily located at the periphery of the lower regions of both lungs.
Two distinctive characteristics of UIP are honeycombing and fibroblast foci (4).
Honeycombing refers to the enlarged air cysts lined with bronchiolar-type
epithelium and filled with mucin and inflammatory cells, while fibroblast foci are
aggregates of fibroblasts and myofibroblasts that are actively producing matrix
proteins (5).
The increasing prevalence and fatality of IPF require people’s awareness.
There are over 180,000 IPF patients in the United States (6). According to an
epidemiological study among Medicare beneficiaries over 65 years of age, the
prevalence of IPF increased dramatically from 202.2 cases per 100,000 personyears in 2001 to 494.5 cases per 100,000 person-years in 2011 (7).
Furthermore, IPF is a disease of aging. It predominantly develops in people
over 55 years old and its incidence increases with aging (8, 9). The median age
at diagnosis is 66 years old (10). Sex and ethnicity also affect susceptibility to
IPF. The incidence in males is higher than that of females (9). Caucasians and
Hispanics are more susceptible than African-Americans and Asians (7).
Mortality also increases with aging and is higher in Caucasians (7, 11). The
survival of IPF is worse than most cancers. The median survival time is 2 to 3
years (10, 12). Its five-year survival is only higher than pancreatic cancer and
lung cancer (13).
The diagnosis of IPF is complex and dependent on a multidisciplinary
approach. Patients usually present with shortness of breath, dry cough and
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fatigue, which are chronic but non-specific. Typically, bibasilar inspiratory
crackles are present in physical exam. Basic information and history of the
patient, including age, sex, smoking status, family history and environmental
exposures need to be carefully evaluated to exclude potential causes. Highresolution computed tomography (HRCT) is usually required. Based on
whether the pattern of HRCT is UIP, how confident the UIP pattern is
established and whether surgical lung biopsy is practical, multidisciplinary
discussion is suggested to determine diagnosis and further management of the
patient (3, 14).
There is no cure for IPF, but several treatments are available to increase
patients’ wellbeing or slow down IPF progression. Pulmonary rehabilitation,
including exercise, emotional support and education, aims to improve overall
physical health and quality of life (15, 16). Supplemental oxygen becomes
necessary during the IPF course at some point (17). Pirfenidone and nintedanib
are the two US FDA approved anti-fibrotic drugs. Their major effect is to slow
down deterioration of patients’ lung function (18, 19). Side effects include
nausea and anorexia for pirfenidone and diarrhea for nintedanib. Both drugs
affect cytochrome P450. Therefore, usage of other drugs and liver function
should be monitored. Though lung transplantation is another option, the
posttransplant survival remains low (20).
Pathogenesis of IPF is multifaceted. Current paradigm focuses on aberrant
wound healing and lung remodeling affected by various factors, including
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genetics, aging, environmental exposures, oxidative stress, interplay between
epithelial cells, inflammatory cells and fibroblasts via cytokines, and interaction
between cells and the environments (matrix or redox) they reside in.
Gene polymorphism and mutation determines susceptibility to IPF. A single
nucleotide polymorphism guanine to thymine in MUC5B promoter has been
confirmed to increase susceptibility (21). Patients with familial pulmonary
fibrosis present symptoms earlier than sporadic IPF (22). Genes encoding
surfactant, telomerase and innate immune-related toll interacting protein are
also associated with IPF (23-26).
Aging is the most important host factor for increasing IPF susceptibility.
Aging is characterized by impaired physiological function and degenerated
biological structure (27). Age-related deficiencies, such as oxidative stress,
genetic instability and epigenetic change are all identified in IPF epithelial cells
or fibroblasts, suggesting the processes of aging overlap with and promote
development of IPF (28). Lung fibroblasts isolated from IPF patients exhibit
cellular senescence compared to those from their age-matched controls (29).
Bleomycin induces more severe lung fibrosis in old mice than young mice via
activating pro-fibrotic TGF-β1/Smad signaling pathway (30).
Recurrent environmental exposures induce repetitive damage that
contribute to IPF development. Cigarette smoke, farming, livestock, dust of
wood, metal, stone, sand and silica all increase IPF risk (31). Among them,
cigarette smoke has the highest public health relevance because of the large
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smoking population (32). Other proposed risk factors for recurrent microinjuries
include viral infection, gastroesophageal reflux, change of lung microbiome,
diabetes mellitus and obstructive sleep apnea (33). Those risk factors are
mostly identified by retrospective case-control studies. Therefore, causal
relationships cannot be established.
Redox homeostasis is disrupted in IPF and oxidative stress has been
implicated in IPF. The lungs are exposed to oxygen directly and sensitive to
oxidative stress. Multiple biomarkers of oxidative stress, including protein
carbonyls, 8-isoprostane and hydroperoxide, are increased (34). Oxidative
stress also induces DNA damage, ECM fragmentation and pro-fibrotic cytokine
activation, all of which promote aberrant wound healing and may increase the
susceptibility to develop IPF (34).
Injured epithelial cells are considered initiators of IPF. In the alveoli, most
epithelial cells are type I alveolar epithelial cells (AECs). They maintain the
shape of alveoli and allow for gas exchange. Damage of type I AECs signals
the progenitor type II AECs to regenerate type I AECs to restore normal lung
structure and function. However, during IPF development, repetitive
microinjuries result in exhaustion of type II AECs (35). Epithelial reprogramming
occurs and is accompanied by change of epithelial morphology (36). Reepithelialization is dysregulated, resulting in pathological honeycombing (37).
Embryonic development pathways, such as Wnt and Sonic hedgehog
pathways, are also reactivated (38, 39). Epithelial cells secret chemokines to
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recruit fibroblasts, growth factors and pro-fibrotic cytokines to induce
proliferation, migration and activation of fibroblasts (37, 40). They also secret
procoagulants to increase the risk of thromboembolism (41). Unfolded protein
response and endoplasmic reticulum stress induce epithelial apoptosis and
epithelial-mesenchymal transition, which play critical roles in IPF pathogenesis
(42, 43).
The role of inflammatory cells in IPF is controversial. There is only mild
inflammation in IPF, and anti-inflammatory therapies are not effective (44).
Whether inflammatory cells are pro- or anti-fibrotic depends on context and
mediators they secret (45).
Fibroblasts are the effector cells. Fibroblasts isolated from lungs of IPF
patients have slower growth rate, flattened shape and decreased telomere
length, indicating replicative senescence (29, 46). They are also activated to
differentiate

into

more

contractile,

invasive

and

apoptosis-resistant

myofibroblasts (47). Myofibroblasts not only originate from local resident
fibroblasts, but also from other resources including circulating bone marrow
derived fibrocytes, pericytes and epithelial- or endothelial-mesenchymal
transition (48). Fibroblasts and myofibroblasts form fibrotic foci, where they
produce exuberant and aberrant ECM proteins and determine the fibrotic
phenotype of IPF (49, 50).
The behavior of fibroblasts is dependent on the interaction between
fibroblasts and their surrounding environment. Serum deprivation-induced
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fibroblast apoptosis is blocked by TGF-β (51). Furthermore, adherent
fibroblasts express α-smooth muscle actin (α-SMA) in response to TGF, while
suspended fibroblasts lose such response (52).
ECM is one important factor that determines fibroblast phenotype. The
function of matrix is to maintain structural framework and elasticity of the lung.
Fibroblasts, which produce ECM, are prone to cluster in areas with higher
matrix stiffness, resulting in aggravation of IPF via a positive feedback loop (53).
Fibroblasts display elongated and dendritic shape, increased proliferation and
migration, decreased apoptosis, increased collagen expression and decreased
expression of proteolysis-associated genes on substrate with higher stiffness
(53).
Comparable to the matrix environment, the redox environment is another
important factor that changes fibroblast behavior. This will be discussed in detail
in the following sections.
No ideal animal models are available for simulating human IPF. Current
animal models are based on injury-induced lung fibrosis without idiopathic or
spontaneous nature. Different models have their own advantages and
disadvantages (54). The most commonly used model is intratracheal
bleomycin-induced lung fibrosis in mice (55). Bleomycin causes breaks of DNA
strands and generation of free radicals specifically in the lung due to lack of its
hydrolase. The major limitations of this model are that bleomycin induces
considerable inflammation and the fibrosis is self-limited, both of which are not
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consistent with IPF (56). This model can be divided into 3 stages including proinflammatory phase, transitional phase and fibrotic phase (57). Other chemicals
to induce lung fibrosis include silica, radiation, asbestos, paraquat and
fluorescent isothiocyanate (58).
1.2 Oxidative stress and its role in IPF
Oxidative stress is classically defined as “an imbalance between prooxidants and anti-oxidants in favor of the former” (59). Although there are some
discrepancies, a plethora of studies have shown oxidative stress is increased
in IPF and contributes to its pathogenesis (34, 60).
Generally, pro-oxidants are increased. Compared to clinical samples from
healthy donors, different kinds of reactive oxygen species (ROS) and oxidation
products of lipids, proteins and DNA are increased in one or more IPF patientsderived samples, including bronchoalveolar lavage (BAL), epithelial lining fluid
(ELF), exhaled breath condensate (EBC), plasma, serum, urine, sputum,
breath, specific type of lung cells and whole lung tissue. Superoxide anion (O2-)
is increased in inflammatory cells from BAL (61). Hydrogen peroxide (H2O2) is
increased in BAL, EBC and serum (61-64). 8-isoprostane is increased in BAL,
EBC, plasma and serum (65-68). Carbonyls are increased in BAL (69, 70).
Nitrotyrosine is increased in EBC, epithelial cells and inflammatory cells (66,
71). Ethane is increased in breath (72). 8-hydroxy-deoxyguanosine (8-OHdG)
is increased in epithelial cells (73). Some studies stratify subjects into smokers
and non-smokers. Malondialdehyde (MDA) is increased in plasma of non-
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smokers with IPF compared to healthy non-smokers (74).
On the other hand, non-enzymatic and enzymatic anti-oxidants are mostly
decreased in IPF samples.
Concentrations of reduced glutathione (GSH) and its oxidized form,
glutathione disulfide (GSSG) are the most commonly measured non-enzymatic
small molecular anti-oxidants. GSH is decreased in plasma (75). GSSG is
increased in BAL and whole blood (76, 77). Total GSH (GSH + 2GSSG) is
decreased in ELF, sputum and whole blood (77-80). The ratio of GSH to GSSG
is decreased in whole blood (77). When smoking status is considered, GSH is
decreased in BAL from non-smoking IPF patients than non-smoking health
controls (74). It’s obvious that the balance of GSH/GSSG redox couple is
disrupted in IPF. GSH is a tripeptide synthesized from cysteine, glutamate and
glycine. In IPF lung tissue, these three amino acids are increased while GSH
synthesis enzymes, including glutamate-cysteine ligase (GCL) and glutathione
synthetase (GSS), are decreased (81). Trolox equivalent anti-oxidant capacity
(TEAC), a measurement of total anti-oxidant capacity, decreased in both BAL
and plasma from IPF patients in non-smoking subjects (74). Surprisingly,
vitamins A, C, E and uric acid, which are generally considered anti-oxidants,
are increased in BAL from IPF patients (76).
Expression or activity of multiple anti-oxidant enzymes are changed in IPF,
further disrupting redox homeostasis. Catalase (CAT) metabolizes H2O2 to
water (H2O) and oxygen (O2). Both CAT expression and activity are decreased
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in IPF lung tissue (82). Glutathione peroxidase (GPX) reduces H2O2 using GSH.
GPX3 is up-regulated in IPF lung tissue (83). Superoxide dismutase (SOD)
transforms O2- to H2O2 and O2. SOD3 is decreased in fibrotic areas of the IPF
lung tissue compared to non-fibrotic areas (84). However, SOD1 is increased
in the serum of IPF patients (85). Glutaredoxin (GRX) uses GSH to reduce
protein S-glutathionylation (deglutathionylation). GRX expression and activity
are decreased in IPF lung tissue (86). Thioredoxin (TRX) reduces intra- or intermolecular disulfide formed from two protein cysteine residues. TRX reductase
regenerates reduced TRX using electrons from reduced nicotinamide adenine
dinucleotide phosphate (NADPH) (87). Immunochemistry staining shows
neither TRX nor TRX reductase is expressed in normal alveolar epithelial cells
(88). However, both TRX and TRX reductase are increased in metaplastic
alveolar epithelial cells in IPF (88). Peroxiredoxin (PRX) metabolizes organic
hydroperoxide (ROOH) and H2O2 to H2O or alcohol (ROH). Overall PRXII is
decreased in IPF lung tissue (89). However, PRXII expression is increased in
hyperplastic epithelium but decreased in fibroblasts foci (89). Sulfiredoxin (SRX)
reduces cysteine sulfinic acid to sulfenic acid. SRX1 is increased in IPF lung
tissue (90). Those cysteine-reducing enzyme systems are interconnected. TRX
and GRX systems can both reduce cysteine disulfide or sulfenic acid back to
thiols, regenerating functional PRX (91). SRX can also activate PRX via
reducing cysteine sulfinic acid and use GSH to catalyze deglutathionylation, as
with GRX (92, 93). Even they share similar functions and their substrates
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overlap, these reducing systems are not entirely replaceable with each other
since their reducing mechanisms are different and their substrate specificity
remains incompletely understood (94).
Although many anti-oxidants are decreased, the fact that some of these
anti-oxidants are still increased and that expression of the anti-oxidant enzymes
are cell type-specific and location-specific in IPF lungs suggest that redox
disturbance in IPF is not simply due to a decrease in anti-oxidants, and that
intricate redox-related regulatory mechanisms exist. Systems controlling
intracellular and extracellular redox environments might be functionally
connected with each other but regulated independently. And those systems
could be differentially impaired during IPF pathogenesis.
Why oxidative stress is increased and how redox imbalance promotes lung
disrepair and fibrosis are incompletely elucidated.
NADPH oxidases (NOXs) and mitochondria are the two major sources of
ROS. Studies based on animal models of lung fibrosis have shown activity of
different isoforms of NOXs are increased, resulting in increased production of
ROS (95). Among them, NOX4 is the only isoform that has been confirmed to
be upregulated in fibroblasts and smooth muscle cells from IPF lungs (96, 97).
Dysfunctional mitochondria are another source of excessive ROS (98). O2 is
partially reduced by electrons leaked from electron transport chain (99).
Furthermore, there is an interplay between mitochondria and NOXs, which
further aggregates ROS production (60).
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Generally, increased oxidative stress induces epithelial apoptosis,
promotes differentiation of fibroblasts into myofibroblasts to secret more
extracellular matrix proteins, recruit inflammatory cells and disrupt the balance
between pro- and anti-fibrotic cytokines. Oxidative stress also results in
chemical modifications of lung matrix proteins, changing not only the structure
and function of specific proteins, but also the biomechanics that might affect the
interaction between fibroblasts and matrices.
There is a vicious cycle between redox imbalance and TGF-β signaling
(100). TGF-β is the major pro-fibrotic cytokine. It is present extracellularly in the
inactive form consisting of dimeric TGF-β, latency-associated protein (LAP) and
latent TGF-β binding protein (LTBP). ROS can activate TGF-β via modifying
and dissociating LAP directly or indirectly via matrix metallopeptidase (MMP)
mediated LAP cleavage (101, 102). ROS can also induce TGF-β expression
(103, 104). On the other hand, TGF-β promotes redox imbalance. NOX4 is upregulated by TGF-β in fibroblasts from control and IPF patients (105).
Mitochondria-derived ROS induced by TGF-β results in mitochondrial DNA
damage and dysfunction in fibroblasts, promoting maladaptation and lung
fibrosis (106). TGF-β also decreases GSH synthesis via inhibiting both catalytic
and modifier subunits of glutamate-cysteine ligase (GCLC and GCLM) in
mouse lung (107). In terms of anti-oxidant enzymes, GRX1 is down-regulated
by TGF-β in A549 cells, an alveolar epithelial cell line derived from lung
adenocarcinoma, and expressions of SOD2 and CAT are suppressed by TGF-
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β in airway smooth muscle cells (108, 109).
Many pro-fibrotic effects on fibroblasts are dependent on ROS. Elimination
of NOX4-produced ROS by N-acetylcysteine (NAC) or inhibition of NOX4
blocks the effects of TGF-β to induce collagen expression and myofibroblast
differentiation of fibroblasts (105). Serum-induced proliferation and invasion of
IPF fibroblasts are blocked by NAC or NOX4 knockdown (110). Even without
treatments, silencing NOX4 results in decreased basal expression of procollagen, fibronectin and α-SMA in IPF fibroblasts (110). ROS over-production
due to mitochondrial dysfunction contributes to IPF fibroblast senescence (111113). Anti-oxidants targeting mitochondria attenuate induction of α-SMA and
NOX4 expression by TGF-β in IPF fibroblasts (114). Exogenous H2O2 increases
α-SMA expression in a dose- and time-dependent manner in control lung
fibroblasts while NAC reduces expressions of α-SMA and type-I collagen in
early passages of IPF fibroblasts (115).
ROS also mediates pro-fibrotic effects on other cell types and modifies
matrix proteins. Anti-oxidants abrogates the effects of exogenous H2O2 to
induce epithelial-to-mesenchymal transition (EMT) for A549 cells (116). SOD1mediated production of H2O2 polarizes macrophages to the M2 phenotype,
promoting lung remodeling and fibrosis (117). H2O2 secreted by IPF fibroblasts
induces small airway epithelial cell death (118). Exogenous H2O2 inhibits wound
healing in a concentration-dependent manner via inducing apoptosis and
suppressing migration of alveolar epithelial cells (119). Bleomycin-generated
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ROS induces endothelial stress and differentiation of pericytes into
myofibroblasts (120). ROS contributes to matrix dysregulation in IPF (121).
Hyaluronic acid, which is increased in BAL from IPF patients, is prone to H2O2induced degradation (122, 123). Syndecan-1 is increased in both BAL and lung
tissue from IPF patients (124). Its shedding and function as neutrophil
chemoattractant are inhibited by SOD1 (124).
Previous clinical trials targeting oxidative stress were unsuccessful.
Compared to placebo, NAC monotherapy did not benefit IPF patients in terms
of slowing down lung function deterioration or decreasing mortality (125).
Surprisingly, NAC triple-therapy with prednisone and azathioprine increased
the rate of death and hospitalization, and the study was terminated after interim
analysis (44). The failure of those studies indicates providing exogenous antioxidants to decrease overall oxidative stress might not be the way to treat IPF
since many oxidants have physiological roles and giving anti-oxidants
indiscriminately may disrupt those normal biological functions. However, NAC
monotherapy was related to a significant decrease of risk of death and disease
progression in patients with a TT genotype of the TOLLIP gene that plays
important roles in lung host defense (26). The genotype-stratified effect further
reveals the complexity of the redox regulation in IPF. Moreover, considering IPF
pathogenesis is multifactorial, and pro-fibrotic pathways overlap and
compensate for each other, interventions with pleiotropic effects might have a
better chance of being effective than highly specific drugs that target a single
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molecule or pathway (126). The ineffectiveness of overall anti-oxidants and
highly selective drugs in general IPF patients facilitates us to think whether
there will be other methods to intervene redox imbalance in a neither too
general nor too specific manner. My proposed intervention against oxidative
stress is manipulating redox couples and their redox potentials to restore redox
homeostasis.
1.3 Redox couples and their roles in lung fibrosis
Redox couples provide a new aspect of studying oxidative stress.
Traditional definition of oxidative stress emphasizes the overall imbalance
between pro-oxidants and anti-oxidants. However, the sensitivity to oxidants
and the response to anti-oxidants of different systems are not the same (127).
Furthermore, traditional definition neglects the signaling role of redox
modification and normal biological functions of specific redox molecules.
Modern concept of oxidative stress adds the results of the redox imbalance,
which are disruption of redox signaling and damage to biological molecules
(128). Compared to ROS, redox couples have the advantage of being easier to
measure and constituting a hierarchical regulatory network themselves (127).
They can buffer oxidative stress and transduce signals via regulating redox
environment or by affecting protein functions through oxidation and reduction
of cysteine thiols (129, 130).
Based on concentrations, cysteine/cystine (Cys/CySS) is the major
extracellular redox couple while GSH/GSSG is the major intracellular redox

15

couple (131). There are several other intracellular redox couples as well, such
as reduced/oxidized Trx and NADPH/NADP+ (132). Redox potential (Eh) is used
to quantitatively describe the reducing ability of a redox couple to buffer
oxidative stress and is calculated from the Nernst equation. Those redox
couples are not in equilibrium with each other, which is another evidence of
inadequacy of traditional balance definition of oxidative stress (131). In fact,
even for a particular redox couple, its redox potential differs significantly in
subcellular compartments (133). Normal human plasma GSH/GSSG redox
potential (Eh(GSH/GSSG)) and plasma Cys/CySS redox couple (Eh(Cys/CySS))
are around -140 mV and -80 mV, respectively (134). Cytoplasmic
Eh(GSH/GSSG) varies between -220 mV and -260 mV while cytoplasmic
Eh(Cys/CySS) is close to -160 mV (133). Mitochondrial Eh(GSH/GSSG) and
nuclear Eh(GSH/GSSG) are more reducing than cytoplasmic Eh(GSH/GSSG)
(135).
Though components of each redox couple are in dynamic status to maintain
relatively stable redox potential, many factors can affect the set-point value of
redox potential. Human plasma Eh(GSH/GSSG) and Eh(Cys/CySS) become
progressively oxidized with aging (136, 137). They are also more oxidized in
smokers compared to non-smokers (138). Plasma Eh(GSH/GSSG) becomes
oxidized over time with chemotherapy (139). Other risk factors related with
oxidation of plasma Eh(GSH/GSSG) or Eh(Cys/CySS) include high serum
cholesterol level, low sulfur amino acid diet and alcohol consumption (140-142).
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Those data also support the concept that redox potentials respond to
endogenous and exogenous disturbance and might be indicators reflecting
combined effects of regulation of redox environment.
Change of redox potential is associated with change of cellular status and
biological process, which might promote development of multiple diseases.
Cytosolic Eh(GSH/GSSG) becomes progressively oxidized during the life cycle
when cells switch from proliferation (-240 mV) to differentiation (-200 mV) to
apoptosis (-170 mV) (143). Oxidation of extracellular Eh(Cys/CySS) from -150
mV to 0 mV stimulates monocyte adhesion, inhibits colorectal adenocarcinoma
epithelial proliferation and increases oxidant-induced retinal pigment epithelial
apoptosis (144-146). Oxidized extracellular Eh(Cys/CySS) stimulates proinflammatory

signaling

in

endothelial

cells,

while

oxidized

plasma

Eh(GSH/GSSG) directly correlates with thickness of carotid intima-media
thickness,

both

of

which

suggest

increased

chance

of

developing

atherosclerosis (147, 148). Plasma Eh(GSH/GSSG) is more oxidized in diabetic
patients (149). For chronic obstructive pulmonary disease (COPD) patients,
plasma Eh(Cys/CySS) is more oxidized (150). Furthermore, loss of lung
function correlates with the extent of plasma Eh(Cys/CySS) oxidation (150).
Severity of human immunodeficiency virus (HIV) infection, which is represented
by CD4-positve T cell count, also correlates with plasma Eh(Cys/CySS) (150).
Reduced extracellular Eh(Cys/CySS) decreases mouse neuronal death via
increasing

GSH

and

decreasing

ROS
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(151).

Reduced

extracellular

Eh(Cys/CySS) also reverses the loss of free reduced nicotinamide adenine
dinucleotide (NADH) in mouse old and Alzheimer’s neurons, protecting against
age-related Alzheimer's disease (152). Oxidized extracellular Eh(Cys/CySS)
induces ROS generation, promotes extracellular signal-regulated kinase (ERK)
phosphorylation and NF-kB expression via activating metabotropic glutamate
receptor 5 (mGlu5), and stimulates inducible nitric oxide synthase (iNOS)
expression in rat glioma C6 cells (153). The oxidized media conditioned by C6
glial cells decrease tyrosine hydroxylase expression in mouse dopaminergic
neuronal MN9D cells, which is neurotoxic and promotes Parkinson’s disease
(153). However, reduced extracellular Eh(Cys/CySS) promotes migration and
invasion of PC3 prostate carcinoma cells via increasing MMP9 activity and
NOX1-mediated H2O2 production (154). Reduced Eh(Cys/CySS) also promotes
proliferation of colon carcinoma Caco-2 cells via metalloproteinase-mediated
epidermal growth factor receptor (EGFR) activation and downstream p44/p42
mitogen-activated protein kinase (MAPK) phosphorylation (155).
Overall, the effects of change of redox potential might be versatile and
dependent on cells and tissues. Oxidizing redox potential might generally
initiate diseases. Reducing redox potential might generally increase cellular
defense against harmful stimulants, thus increasing cancer cell survival and
promoting disease progression. However, whether oxidation or reduction is
beneficial for patients is determined on a case-by-case basis and might be
dependent on the disease course or stage. The underlying mechanisms are not
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well studied and might involve a combination of disturbing intracellular redox
environments, influencing post-translational modifications and functions of
proteins and affecting multiple signal transduction pathways.
Particularly, changes of redox potential contribute to lung fibrosis. Oxidized
extracellular Eh(Cys/CySS) stimulates proliferation of primary mouse lung
fibroblasts and fibronectin expression via activating protein kinase C, upregulating TGF-β1 and cAMP response element binding protein (CREB) (156).
NF-kB and Smad3 levels are also increased (156). The pro-fibrotic effects
require thiol/disulfide interaction as conjugating thiols with chemical reagents
blocks fibronectin induction (156). In bleomycin-induced lung fibrosis mouse
model, oxidation of plasma Eh(GSH/GSSG) coincides with the pro-inflammatory
phase while oxidation of plasma Eh(Cys/CySS) occurs during the fibrotic phase
(57). ELF Eh(Cys/CySS) is oxidized to a greater degree than plasma
Eh(Cys/CySS) and occurs before the fibrotic phase (57). Those suggest
oxidation of redox couples might precede appearance of the fibrotic phenotype
and represent a predisposing state with increased susceptibility to injuries from
internal and external detrimental exposures.
Oxidative stress increases with aging and is considered an age-related
defect. Aging is the most striking risk factor for IPF, and indicators of redox
imbalance are observed in and contribute to IPF. Oxidation of redox couples
accompanies aging in human plasma. Oxidation of redox couples also
regulates multiple signaling pathways in vitro, including stimulation of pro-
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fibrotic cellular responses in mouse lung fibroblasts, and precedes bleomycininduced lung fibrosis in vivo. The downstream effects of oxidized redox potential
have been explored while the upstream mechanism of whether and how redox
potential are regulated remains unknown. Following study reveals the
relationship between redox couples and mouse lung fibroblasts is reciprocal.
Fibroblasts actively regulate their extracellular Eh(Cys/CySS) in culture (157). A
set-point value is reached and maintained for both fibroblasts from young and
old mice regardless of whether the initial incubating media are oxidizing or
reducing (157). The only difference between young and old fibroblasts is that
the set-point value is more oxidizing for old fibroblasts, which is consistent with
increased susceptibility of pro-fibrotic responses (157).
Slc7a11 expression is lower in old fibroblasts compared to young fibroblasts
(157). It is the light chain subunit of a membrane-bound CySS/glutamate
antiporter system Xc- (158). System Xc- imports CySS and exports glutamate
with 1:1 exchange ratio. Inside the cells, CySS can be reduced to Cys, which
is the rate-limiting component of GSH synthesis. Expression of Slc3a2, which
is the other subunit of system Xc- and also known as 4F2 heavy chain (4F2hc)
or CD98, is not different between young and old fibroblasts (157, 159, 160).
Therefore, Slc7a11 might determine the activity of system Xc- and is considered
to be a candidate to regulate extracellular Eh(Cys/CySS) in primary mouse lung
fibroblasts.
1.4 Specific aims
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IPF develops insidiously. Honeycombing involves destruction of basement
membrane and is not reversible. By the time patients are diagnosed, extensive
fibrosis characterized by widespread fibrotic foci and honeycombing has
already formed, there is no available treatment to reverse the fibrosis. Therefore,
identifying subclinical stage of IPF will probably provide patients with the utmost
benefits. Since change of redox potential might precede detectable lung fibrosis,
it is critical to understand how redox potential is regulated and whether redox
potential is targetable to modify extracellular and intracellular redox
environments so that lung redox homeostasis is restored, and the susceptibility
of fibrosis is not increased.
This dissertation aims to investigate whether Slc7a11 mediates agedependent change of extracellular and intracellular redox potentials and how
Slc7a11 affects intracellular signaling pathways in primary mouse lung
fibroblasts. Redox potentials between fibroblasts from IPF patients and nonIPF donors will be compared and the role of Slc7a11 in human fibroblasts will
also be explored.
Aim 1: To determine whether age-dependent Slc7a11 expression controls
extracellular Eh(Cys/CySS) in primary mouse lung fibroblasts.
My data indicate that Slc7a11 can be a potential controller of extracellular
Eh(Cys/CySS) and therefore a switch of pro-fibrotic responses in fibroblasts.
The experiments in Aim 1 will be composed of pharmacological and genetic
manipulations of Slc7a11 expression to validate the regulatory role of Slc7a11.

21

Whether Slc7a11 controls the balance of Cys/CySS and GSH/GSSG redox
couples and their redox potentials extracellularly and intracellularly will be
explored. The efficacy of sulforaphane to induce Slc7a11 will be demonstrated
to establish the potentiality of sulforaphane as a drug to restore redox
homeostasis in further clinical trials.
Aim 2: To uncover which protein cysteines and pathways are changed with
aging and responsive to Slc7a11-dependent restoration of intracellular redox
environment in primary mouse lung fibroblasts.
Aging changes intracellular redox environment and protein oxidation.
However, whether Slc7a11 affects intracellular redox environment, to what
degree Slc7a11 reverses the effects of aging on intracellular redox environment,
and what responses Slc7a11-dependent change of redox environment induce
in fibroblasts remain unknown. Thiols of cysteine residues in multiple proteins
are targets of various redox modifications. Change of cysteine redox state,
which is defined as the ratio of oxidized to reduced form of a specific cysteine
thiol, might determine the activity of the cysteine-containing protein and affect
downstream signaling pathways. Redox proteomics will be applied in Aim 2 to
identify these intracellular protein cysteines whose redox states are altered with
aging and in response to Slc7a11 manipulation. Biological processes and
functions those proteins are involved in will be analyzed to elucidate agedependent and Slc7a11-sensitive signaling pathways in fibroblasts.
Aim 3: To compare SLC7A11 and redox environments in human lung
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fibroblasts from non-IPF donors and IPF patients.
The purpose of Aim 3 will be to demonstrate that the mechanisms explored
in the first 2 Aims are directly applicable to humans. Primary human lung
fibroblasts from patients with IPF and from non-IPF controls will be obtained.
SLC7A11 expression, extracellular Eh(Cys/CySS), intracellular Eh(GSH/GSSG)
and expression of pro-fibrotic genes will be measured in these human lung
fibroblasts. This Aim will show the similarity between mouse and human lung
fibroblasts and serve as an intermediate step between animal experiments and
clinical trials.
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CHAPTER II

AGE-DEPENDENT OXIDATION OF EXTRACELLULAR
CYSTEINE/CYSTINE REDOX STATE (EH(CYS/CYSS)) IN MOUSE LUNG
FIBROBLASTS IS MEDIATED BY A DECLINE IN SLC7A11 EXPRESSION

2.1 Introduction
Reversible reduction and oxidation (redox) of the sulfur-containing amino
acid cysteine (Cys) is exploited for a large number of biological processes (87).
Redox reactive Cys can be found as the free amino acid, as part of the thiol
antioxidant

glutathione

(γ-glutamylcysteinylglycine;

GSH),

or

as

functional/regulatory sites within proteins (143). Cys and its oxidized form,
cystine (CySS), constitute a redox couple that can be expressed in terms of its
redox potential, or Eh value. Likewise, GSH and its disulfide form, abbreviated
GSSG, comprise another redox couple. These 2 couples are functionally
connected but differentially regulated (127). Cys and CySS are present in
greater concentrations than GSH and GSSG outside of cells, whereas GSH
and GSSG predominate within the intracellular compartment (161, 162). In
addition, each couple and each compartment are maintained at different redox
potentials (147). Therefore, it is important to specify which compartment is
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being considered when reporting redox potentials. Both intracellularly and
extracellularly Cys/CySS and GSH/GSSG function as redox buffers to maintain
redox homeostasis (143) and resist or facilitate oxidation of protein thiols to
change protein functions and transduce signals (163, 164). Thus, changes in
redox potential can have a dramatic effect on cellular function. For example,
oxidation of extracellular Eh(Cys/CySS) suppressed proliferation and inhibited
signal transduction in Caco2 cells (155, 165), increased pro-inflammatory IL-1β
in human monocytic U937 cells (166), and stimulated proliferation and profibrotic gene expression in mouse lung fibroblasts (156).
Oxidation of the extracellular space is reflected in changes in plasma redox
potentials. In vivo studies have shown that plasma Eh(Cys/CySS) was oxidized
in mice with bleomycin-induced lung injury (57), and in rats with kainic acid and
pilocarpine-induced epilepsy (167). In humans, plasma Eh(Cys/CySS) was
found to be more oxidized in adults chronically exposed to arsenic (168), adults
acutely exposed to acetaminophen (169), and in children with autism (170).
Thus, oxidation of the extracellular environment, or redox stress, is associated
with disease processes and environmental or pharmacological exposures.
Aging is a risk factor for development of a number of chronic diseases. One
way in which aging may promote disease development or progression is by
changing the set-point of the redox buffering systems. Aging is associated with
a steady oxidation of plasma Eh(Cys/CySS) (136), but the mechanisms
responsible are unclear. Cells in culture maintain an Eh(Cys/CySS) remarkably
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close to the redox potential of plasma (145, 155, 171), suggesting that cells are
actively involved in controlling their immediate extracellular redox environment.
Previous study showed that lung fibroblasts from old mice (24 months old)
produced an extracellular Eh(Cys/CySS) that was more oxidized than that
produce by their young counterparts (2 months old) (157).
Differential gene expression analysis revealed that Slc7a11 was downregulated in old mouse lung fibroblasts (157). Slc7a11 (also called xCT) is the
light chain of system Xc- which transports CySS into cells and exports
glutamate with 1:1 as the exchange ratio (172). Previous studies have
suggested that Slc7a11 expression is linked to control of the extracellular
Cys/CySS redox state. Mice lacking Slc7a11 have a more-oxidizing
extracellular Eh(Cys/CySS), as evidenced by an increase in their plasma CySS
concentrations that is not balanced by a corresponding increase in plasma Cys
(173). Conversely, stimulation of B cell differentiation is accompanied by an
upregulation of Slc7a11 and an increase in extracellular Cys concentration
(174). In the latter study there was also an increase in intracellular GSH,
consistent with other studies showing that Slc7a11 activity supports intracellular
GSH levels by supplying Cys, which is the rate-limiting amino acid for its
synthesis (175). The purpose of the present study was to determine whether
down-regulation of Slc7a11 in fibroblasts from old mice was sufficient to explain
the oxidation of the extracellular redox environment associated with aging, and
to determine whether synthesis of intracellular GSH was a pre-requisite for this
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effect.
2.2 Materials and methods
2.2.1 Reagents
Reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Corning
(Manassas, VA) unless otherwise specified.
2.2.2 Primary lung fibroblasts culture
Lung fibroblasts were isolated from young (3 months) or old (24 months)
female C57BL/6 mice (157). Mouse lungs were harvested and cut into 1 mm
sections (176). Those lung sections were washed with sterile phosphatebuffered saline (PBS) and resuspended in RPMI-1640 with L-glutamine
containing 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution
(176). Those tissues were transferred to cell culture dishes and incubated in a
humidified 5% CO2 incubator at 37°C for 7 to 21 days to let fibroblasts migrate
out of tissues (176). Animal use was approved by the Institutional Animal Care
and Use Committee of the University of Louisville. DMEM with 10% FBS and
1% antibiotic-antimycotic solution were used for regular cell culture (176).
Fibroblasts between passage numbers 8 and 15 were used in the experiments.
2.2.3 Preparation of redox media
Redox media refers to media with specific Cys and CySS concentrations to
achieve a specific redox state. DMEM without Met or Cys was used to make
redox media. For 0 mV (oxidizing) media, 99.75 μM CySS and 0.5 μM Cys were
added. All redox media were freshly prepared immediately before use.

27

2.2.4 Pharmacological treatment of fibroblasts
For sulforaphane experiments, primary lung fibroblasts from old mice were
seeded in 6-well plates at the density of 1,000,000 cells/well in DMEM
containing 10% FBS and 1% antibiotic-antimycotic solution. After 24 hours, the
media was changed in the induction group to fresh DMEM with 5 μM
sulforaphane. In the controls, media was changed to fresh DMEM. After
incubation for 4 hours, media was changed to 0 mV redox media and incubated
for another 24 hours. Afterwards, media was collected for HPLC analysis and
cells for qPCR analysis.
For sulfasalazine experiments, young fibroblasts were used. Twenty four
hours after plating, media were changed to 0 mV redox media with or without
300 μM sulfasalazine. Four hours later, cells and media were collected.
For L-buthionine sulfoximine experiments, young fibroblasts were
incubated with or without 20 µM L-buthionine sulfoximine for 24 hours followed
by 4 hours 0 mV redox media incubation. Afterwards, cells and media were
collected.
2.2.5 Genetic manipulation of Slc7a11 expression in lung fibroblasts
Plasmid transfection was used to over-express Slc7a11 in old fibroblasts,
while siRNA was used to knock down Slc7a11 in young fibroblasts. Plasmid
encoding mouse Slc7a11 was from Origene Technologies, Inc. (Rockville, MD),
and siRNA was from Dharmacon (Lafayette, CO). Plasmid LacZ encoding for
beta-D-galactosidase and non-targeted NT2 were used as plasmid and si-RNA
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control. Two μg of plasmid and 30 pmol of siRNA were used for electroporation.
Electroporation was conducted using Mode U-023 in NucleofectorTM 2b Device
(Lonza, Allendale, NJ) following the protocol in the AmaxaTM Basic
NucleofectorTM Kit for Primary Mammalian Fibroblasts (Lonza, Allendale, NJ).
One million fibroblasts were used for each electroporation and then plated in 6well plates. Serum-free and antibiotic-free DMEM were used to incubate the
transfected cells. After 24 hours recovery, DMEM were changed to 0 mV media
for 4 hours incubation. Then, media and cells were collected.
2.2.6 Media derivatization and HPLC analysis
Collected media were centrifuged at 800g for 4 minutes to pellet the
suspended fibroblasts. Five hundred μl cell-free media were combined with 500
μl ice-cold 10% (w/v) perchloric acid (PCA), 0.2 M boric acid and 20 μM γglutamyl glutamate (177). These samples were derivatized by iodoacetic acid
and dansyl chloride, and then analyzed by HPLC (Waters Corporation, Millford,
MA) (178). For derivatization, 300 μl of the media-PCA mixture were combined
with 60 μl of freshly prepared 14.8 mg/ml sodium iodoacetate. Then, the pH of
the solution was adjusted to 9.0 ± 0.2 with 1 M potassium hydroxide. The
sample was incubated at room temperature for 20 minutes and mixed with 300
μl of freshly prepared 20 mg/ml acetone-dissolved dansyl chloride. After that,
the sample was vortexed and incubated in the dark at room temperature for 24
hours. On the next day, 500 μl of chloroform were added and the solution
underwent vortex for 10 seconds. The top aqueous layer was used for
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concentration measurements by HPLC. Concentrations of Cys, CySS, GSH,
GSSG, CySSG were measured by integration relative to the internal standard
γ-glutamyl glutamate. Total Cys concentration = [Cys]+2*[CySS]+[CySSG] and
total GSH concentration = [GSH]+2*[GSSG]+[CySSG]. Eh of Cys/CySS and
GSH/GSSG were calculated according to the Nernst equation for pH 7.4:
Eh(Cys/CySS)

=

-250+30*log([CySS]/[Cys]2);

Eh(GSH/GSSG)

=

-

264+30*log([GSSG]/[GSH]2) (179).
2.2.7 Measurement of Slc7a11, Gclc and Nqo1 mRNA level
RNAqueous®-4PCR Kit (Thermo Fisher Scientific, Waltham, MA) was used
for DNA-free RNA isolation from primary mouse lung fibroblasts. SuperScript™
VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) was used
for cDNA synthesis. Real-time quantitative PCR (qPCR) was conducted to
measure Slc7a11, Gclc, Nqo1 and Gapdh mRNA expression with TaqMan
probes

(TaqMan®

Gene

Expression

Assay

Mm00442530_m1,

Mm00802655_m1, Mm01253561_m1, Mm99999915_g1; Applied Biosystems),
according to the manufacturer’s protocol (TaqMan Universal Master Mix II;
Applied Biosystems). Step One Plus Real Time PCR System (Applied
Biosystems) was used for qPCR with the parameters: 50°C 2 minutes, 95°C
10 minutes, followed by 40 cycles of 95°C 15 seconds and 60°C 1 minute.
Results were analyzed using Step One Software version 2.3 (Applied
Biosystems). The amplification curves were analyzed by the mathematical
equation of the second derivative, and the amounts of Slc7a11, Gclc, Nqo1
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mRNA expression were normalized to the housekeeping gene Gapdh mRNA
expression. The 2-ΔΔCT method was used to calculate relative quantification
(180).
2.2.8 Measurement of Slc7a11 activity
Slc7a11 activity was measured as the rate of glutamate release. Fresh 0
mV media containing 100 µM CySS and 0 µM glutamate were added to cells,
and aliquots of conditioned media were removed at 15-minute intervals.
Glutamate

concentrations

in

media

were

measured

using

the

Glutamate/Glutamate Oxidase assay kit from Molecular Probes (Waltham, MA)
according to manufacturer’s recommendations. L-glutamate was oxidized by
glutamate oxidase to produce α-ketoglutarate, ammonia and hydrogen
peroxide. L-alanine and L-glutamate-pyruvate transaminase were used to
regenerate L-glutamate by transamination of α-ketoglutarate to amplify the
signal. Large amounts of hydrogen peroxide were produced and reacted with
the Amplex® Red reagent in a 1:1 stoichiometry to generate fluorescent
resorufin that could be detected.
2.2.9 Statistical analysis
Data were presented as mean ± standard deviation. Significance was
evaluated by one-way ANOVA and unpaired two-tailed t-test. Linear regression
was used to assess differences between rates of glutamate release.
2.3 Results
2.3.1 Manipulation of Slc7a11 by pharmacological agents
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Consistent with the previous studies (157), primary lung fibroblasts from old
mice had lower expression of Slc7a11 (Figure 2.1.A) and more oxidized
extracellular Eh(Cys/CySS) redox potential (Figure 2.1.B) relative to fibroblasts
from young mice. To begin to assess whether expression level of Slc7a11 was
responsible for the observed differences in the extracellular redox states of
young and old fibroblasts, old fibroblasts were treated with sulforaphane, an
Nrf2 inducer known to increase expression of Slc7a11 (181). Sulforaphane
increased Slc7a11 expression in old cells to the level seen in young cells
(Figure 2.1.A). Sulforaphane also reduced extracellular Eh(Cys/CySS) to the
value seen in young cells (Figure 2.1.B). There was no significant difference in
the concentration of CySS in the conditioned media from cultures of young and
old fibroblasts (Figure 2.1.C). Rather, a decrease in the amount of Cys (Figure
2.1.D) that accumulated in the media was responsible for the 30 mV oxidation
of old fibroblasts conditioned media.
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Figure 2.1 Sulforaphane treatment of old fibroblasts restored Slc7a11
expression and extracellular Eh(Cys/CySS) to the levels seen in young
fibroblasts. Primary lung fibroblasts from young and old mice were incubated in
DMEM with or without 5 μM sulforaphane for 4 hours followed by 24 hours
incubation in 0 mV redox media. (A) Slc7a11 mRNA expression, (B)
extracellular Eh(Cys/CySS), (C) extracellular Cys concentration, and (D)
extracellular CySS concentration, were measured as described in Materials
and Methods. Data are expressed as mean ± standard deviation of 3
independent replicates. * - Indicates p<0.05 compared to untreated young
fibroblasts.
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Extracellular glutathione concentrations were also different between
cultures of young and old fibroblasts. GSH, GSSG and the mixed disulfide
between CySS and GSH (abbreviated CySSG) were all lower in the conditioned
media from old cells compared to young cells (Figure 2.2.A). There was a larger
decrease in GSH than in GSSG; as a result, the redox potential of this couple
(Eh(GSH/GSSG)) was 30 mV more oxidized in the old cultures than in the young
(Figure 2.2.B). GSH was not present in the 0 mV redox media initially. Therefore,
the appearance of GSH indicated that it was released from the cells. To facilitate
analysis of GSH export, the total GSH pool size was calculated by combining
GSH contributed by all 3 forms: GSH, GSSG and CySSG. As shown in Figure
2.2.C, total GSH was 4-fold lower in old fibroblasts than in young fibroblasts.
Sulforaphane treatment restored extracellular GSH, GSSG, CySSG, total GSH
and Eh(GSH/GSSG) in old cultures to the levels seen in cultures of young
fibroblasts (Figure 2.2.A-C).

34

Figure 2.2 Glutathione was less abundant and more oxidized in the conditioned
media of old fibroblasts, and sulforaphane corrected these deficiencies.
Primary lung fibroblasts from young and old mice were incubated in DMEM with
or without 5 μM sulforaphane for 4 hours followed by 24 hours incubation in 0
mV redox media. (A) CySSG, GSH and GSSG, were measured in the
conditioned medium by HPLC. (B) Extracellular Eh(GSH/GSSG) was calculated
from the Nernst equation. (C) Total GSH concentration was calculated
according to the formula: Total Cys = CySSG + GSH + 2*GSSG. Data are
expressed as mean ± standard deviation of 3 independent replicates. * 35

Indicates p<0.05 compared to untreated young fibroblasts.
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Sulforaphane is known to induce the expression of a number of antioxidant
genes via its activation of the transcription factor Nrf2 (182). To determine the
extent to which the effects of sulforaphane on extracellular E h(Cys/CySS) are
mediated by Slc7a11 as opposed to its other transcriptional targets, cells were
first transfected with siRNA to knock down Slc7a11 and then treated with
sulforaphane. The results in Figure 2.3 showed that extracellular Eh(Cys/CySS)
no longer became more reduced in response to sulforaphane in cells depleted
of Slc7a11 (Figure 2.3.A). Expression of Slc7a11 was still induced by
sulforaphane in the knock down cells, but not to the level seen in control cells
(Figure 2.3.B). In contrast, other Nrf2 target genes (Gclc and Nqo1) were
induced equally well in both control and knock down cells (Figures 2.3.C and
2.3.D).
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Figure 2.3 Reduction of extracellular Eh(Cys/CySS) in response to
sulforaphane is mediated by Slc7a11. Primary lung fibroblasts from old mice
were transfected with siRNA targeting Slc7a11 (si-Slc7a11) via electroporation.
Non-targeting siRNA was electroporated as control. Fibroblasts were plated,
and 24 hours later the media were changed to fresh DMEM with or without 5
μM sulforaphane for 4 hours. After that, media were changed to 0 mV redox
media for 4 hours. (A) Extracellular Eh(Cys/CySS), (B) Slc7a11 mRNA
expression, (C) Gclc mRNA expression, and (D) Nqo1 mRNA expression, were
measured as described in the legends to Figures 2.1 and 2.2. Data are
expressed as mean ± standard deviation of 3 independent replicates. * Indicates p<0.05 between sulforaphane-treated and untreated fibroblasts.
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Having shown that a drug that increased Slc7a11 expression also reduced
extracellular Eh(Cys/CySS), I sought to demonstrate that the inverse was also
true: that inhibition of system Slc7a11 activity would oxidize extracellular
Eh(Cys/CySS). For this purpose, sulfasalazine, an inhibitor of CySS transport
that acts on the Slc7a11 subunit of system Xc-, was used(183). As predicted,
sulfasalazine

treatment

of

young

fibroblasts

oxidized

extracellular

Eh(Cys/CySS) by 30 mV (Figure 2.4.A). This oxidation was due to a significant
decrease in the concentration of extracellular Cys, while extracellular CySS
concentration was unaffected by sulfasalazine (Figure 2.4.B and 2.4.C).
Inhibition of Slc7a11 activity had no effect on accumulation of total GSH in the
conditioned media (Figure 2.4.D).
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Figure 2.4 Slc7a11 inhibition by sulfasalazine in young mice lung fibroblasts
resulted in oxidation of extracellular Eh(Cys/CySS). Primary lung fibroblasts
from young mice were incubated in 0 mV redox media with or without 300 μM
sulfasalazine (SASP) for 4 hours. Conditioned media were collected for
analysis by HPLC. (A) Eh(Cys/CySS), (B) Cys concentration, (C) CySS
concentration and (D) total GSH concentration were determined as described
in the legends to Figures 2.1 and 2.2. Data are expressed as mean ± standard
deviation of 3 independent replicates. * - Indicates p<0.05 compared to
untreated young fibroblasts.
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Not only Slc7a11 mRNA, but also the activity of Slc7a11-mediated transport
was lower in fibroblasts from old mice (Figure 2.5). Because Slc7a11 exports a
glutamate for every CySS it imports, accumulation of glutamate in the media
was measured as a function of time to assess transport activity. This approach
avoided having to account for the multiple fates of CySS once imported into the
cell.

Using

this

approach,

the

pharmacological

manipulations

were

demonstrated to translate to changes in activity. Sulforaphane increased
Slc7a11 transporter activity (Figure 2.5.A), whereas sulfasalazine inhibited
activity (Figure 2.5.B).
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Figure 2.5 Slc7a11 transport activity was increased by sulforaphane and
inhibited by sulfasalazine. (A) Glutamate release by old fibroblasts with or
without sulforaphane treatment. Primary lung fibroblasts from old mice were
incubated in DMEM with or without 5 μM sulforaphane for 4 hours followed by
20 hours incubation in 0 mV redox media. After that, media were changed to
fresh 0 mV media, and media was collected at 15 min, 30 min, 45 min and 60
min for measuring extracellular glutamate as described in Materials and
Methods. (B) Glutamate release by young fibroblasts with or without
sulfasalazine treatment. Primary lung fibroblasts from young mice were
incubated in 0 mV media with or without 300 μM sulfasalazine. Media were
collected at 15 min, 30 min, 45 min and 60 min for measuring extracellular
glutamate. Data are expressed as mean ± standard deviation of 3 independent
replicates. * - Indicates p<0.05 between treated and untreated fibroblasts.
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2.3.2 Modulation of Slc7a11 expression via genetic methods
Because pharmacological agents can have off-target effects, I next
attempted to verify the above results using transfection to overexpress and
knock down Slc7a11 in old and young fibroblasts. Similar to the results with
induction by sulforaphane, transfection of old fibroblasts with a Slc7a11encoding plasmid increased Slc7a11 mRNA expression by three-fold (Figure
2.6.A) and reduced the extracellular Eh(Cys/CySS) by 30 mV (Figure 2.6.B).
Conversely, siRNA-mediated knock down of Slc7a11 in young fibroblasts
decreased Slc7a11 mRNA level by three-fold (Figure 2.6.C). Correspondingly,
extracellular Eh(Cys/CySS) became 45 mV more oxidized after Slc7a11 knockdown (Figure 2.6.D). The changes in extracellular Eh(Cys/CySS) were largely
driven by differences in Cys concentrations. Neither overexpression nor knock
down had a significant effect on extracellular CySS concentrations (Figure 2.7.A
and 2.7.B). However, Slc7a11 over-expression in old cells significantly
increased extracellular Cys from 2 μM to 5 μM while Slc7a11 knock-down in
young cells significantly decreased extracellular Cys from 6 μM to 1 μM (Figure
2.7.C and 2.7.D). Neither overexpression nor knock down of Slc7a11 had a
significant effect on the accumulation of extracellular GSH (Figure 2.7.E and
2.7.F).
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Figure 2.6 Effect of genetic manipulation of Slc7a11 on extracellular
Eh(Cys/CySS). Primary lung fibroblasts from old and young mice were
transfected with either an Slc7a11-encoding plasmid (pSlc7a11) or siRNA
targeting Slc7a11 (si-Slc7a11) via electroporation. Controls were electroporated
with pLacZ or non-targeting siRNA. Fibroblasts were plated, and 24 hours later
the media were changed to 0mV redox media for 4 hours. (A) Slc7a11 mRNA
expression and (B) extracellular Eh(Cys/CySS) in old fibroblasts with and
without overexpression of Slc7a11. (C) Slc7a11 mRNA expression and (D)
extracellular Eh(Cys/CySS) of young fibroblasts with and without knock down of
Slc7a11. Data are expressed as mean ± standard deviation of 3 independent
replicates. * - Indicates p<0.05 compared to controls.
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Figure 2.7 Overexpression of Slc7a11 increased, and knock down of Slc7a11
decreased, extracellular Cys concentrations. Primary lung fibroblasts from old
and young mice were transfected with either pSlc7a11 (overexpression) or siSlc7a11 (knock down), as described in the legend to Figure 2.4. (A and B)
Extracellular CySS concentrations, (C and D) extracellular Cys concentrations,
and (E and F) total extracellular GSH concentrations in old and young
fibroblasts, respectively. Data are expressed as mean ± standard deviation of
3 independent replicates. * - Indicates p<0.05 compared to controls.
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Both Cys and GSH can be exported by cells and used to reduce an oxidized
extracellular Eh(Cys/CySS). To determine whether metabolism of Cys to GSH
is necessary for cells to reduce an oxidizing extracellular E h(Cys/CySS),
buthionine sulfoximine (BSO) was used to inhibit GSH synthesis by γglutamylcysteinyl ligase. As shown in Figure 2.8, 24 hours pre-treatment with
BSO dramatically lowered intracellular GSH (Figure 2.8.A). The inhibition of
GSH synthesis by BSO also led to a dramatic decrease in extracellular GSH
concentrations (Figure 2.8.B). BSO treatment had no effect on extracellular Cys
concentration (Figure 2.8.C) or the ability of cells to restore extracellular
Eh(Cys/CySS) within 4 hours of challenge with 0 mV media (Figure 2.8.D),
suggesting that GSH synthesis was not required for the normalization of an
oxidizing extracellular Eh(Cys/CySS).
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Figure 2.8 Glutathione depletion with BSO did not affect extracellular Cys
concentration or Eh(Cys/CySS). Primary lung fibroblasts from young mice were
incubated in 0 mV redox media with or without 20 µM L-buthionine sulfoximine
(BSO) for 24 hours. (A) Total intracellular GSH. (B) Total extracellular GSH. (C)
Extracellular Cys concentration. (D) Extracellular Eh(Cys/CySS). Data are
expressed as mean ± standard deviation of 3 independent replicates. * Indicates p<0.05 compared to controls.
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2.4 Discussion
The current studies confirm the finding that Slc7a11 expression was lower
in primary lung fibroblasts from old mice than in those from young mice, and
that this was associated with increased oxidation of extracellular Eh(Cys/CySS)
redox potential (157). Those findings have now been extended by investigating
the mechanistic link between these two observations. Up-regulation of Slc7a11
expression by either sulforaphane treatment or transient transfection was
sufficient to restore the ability of lung fibroblasts from old mice to reduce their
extracellular Eh(Cys/CySS) to the level achieved by those from young mice.
Conversely, inhibition of Slc7a11 activity by either sulfasalazine treatment or
siRNA-mediated knock down produced young fibroblasts that resembled old
fibroblasts in terms of their extracellular redox potential. Taken together, these
findings show that Slc7a11 activity is the major determinant of the extracellular
redox environment produced and maintained by primary lung fibroblasts.
In each of the studies presented here, Slc7a11 was positively correlated
with extracellular Cys concentrations. This suggests that intracellular reduction
of CySS to Cys, and the subsequent export of Cys, is limited by the rate of
delivery of CySS to cells. Differences in Slc7a11 activity had no effect on
extracellular CySS concentrations under the culture conditions used in this
study. This is most likely a reflection of the process by which cells regulate their
extracellular redox environment. CySS cannot be reduced to Cys in the
extracellular space. Therefore, cells adjust the relative proportions of
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extracellular CySS and Cys by importing CySS, reducing it to Cys, and then
exporting Cys via system alanine-serine-cysteine (system ASC) (184-187). To
achieve physiological redox potential of about -80 mV (136), only a fraction of
the media CySS needed to be reduced to Cys. Because each molecule of CySS
yields 2 molecules of Cys, very little CySS is consumed in the process of
normalizing the extracellular redox potential. Thus, CySS import via Slc7a11
appears to be the rate-limiting factor for intracellular Cys formation and export,
just as it is rate-limiting for GSH synthesis in some cell types (188, 189).
An increase in extracellular Cys, but not CySS, in response to increased
Slc7a11 activity has been observed previously. Overexpression of Slc7a11 in
Burkitt’s Lymphoma cells was associated with increased extracellular Cys
concentrations (190), similar to my results. In contrast, knock out mice had
elevated plasma CySS, but no change in plasma Cys (173). The discrepancy
between these findings and my results with sulfasalazine or siRNA-mediated
knock down of Slc7a11 may have been due to the fact that the fibroblasts used
in the current studies do not completely lack Slc7a11, or it could be the
presence of other cell types in the mice that may remove Cys from the plasma
(191).
Of the 3 component amino acids of GSH, Cys is usually present at the
lowest concentrations within cells and limits the rate at which GSH can by
synthesized (175). Therefore, changes in Slc7a11 activity can affect
intracellular GSH production. In cancer cells, elevated Slc7a11 expression is
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associated with increased resistance to chemotherapy drugs (192). Conversely,
inhibition of CySS transport can sensitize cancer cells to radiation therapy (193).
The age-related decrease in Slc7a11 expression observed in the current study
may limit GSH synthesis and contribute to lower extracellular concentrations of
GSH.
CySS and GSH have many fates both extracellularly and intracellularly,
complicating efforts to account for contributions of metabolism and transport to
changes in concentrations in any given location. Extracellular GSH can be used
to increase extracellular Cys concentrations by two mechanisms: it can undergo
thiol-disulfide exchange with extracellular CySS to yield Cys and the mixed
disulfide CySSG, or it can be catabolized enzymatically by gammaglutamyltransferase and dipeptidase to yield Cys and the other two component
amino acids of GSH, glutamate and glycine (175).

GSH can also be oxidized

to GSSG and used to glutathionylate extracellular proteins. Similarly, CySS can
cysteinylate proteins. Extracellular Cys itself can be taken up by some cell types
through other amino acid transporters such as systems ASC, EAAT and LAT2
(194, 195). Once CySS is imported, it can be reduced to Cys either nonenzymatically through thiol-disulfide exchange with GSH or enzymatically by
Txnrd1 or Txndc17 (186). Intracellular Cys can be used to synthesize proteins
or GSH, which can then by oxidized, glutathionylate proteins, conjugate to
electrophilic metabolites, or be exported. Despite the complexity of these
interconnected pathways, my data point to a rather straightforward relationship
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between Slc7a11 activity and extracellular Eh(Cys/CySS). Importantly, GSH
was not involved in regulation of extracellular Eh(Cys/CySS), and that
accumulation of Cys in the extracellular space was directly related to the level
of Slc7a11 activity.
Extracellular GSH was less abundant and more oxidized in cultures of lung
fibroblasts from old mice. Whereas sulforaphane treatment corrected these
defects, Slc7a11 overexpression did not. A likely explanation for this
discrepancy is that sulforaphane activates a much broader antioxidant
response than does Slc7a11 overexpression alone. For example, my study
confirmed that, in addition to Slc7a11 induction, sulforaphane upregulated the
expression of Gclc, the catalytic subunit of the rate-limiting enzyme in GSH
synthesis. Both Slc7a11 and Gclc are transcriptionally regulated by the
transcription factor Nrf2. Sulforaphane is an electrophile that interacts directly
with nucleophilic residues on Keap1, thereby activating Nrf2 (196). In cancer
cells, sulforaphane can induce anticancer responses driven in part through
production of reactive oxygen species via interactions with mitochondrial
respiratory complex I (197). Oxidative stress produced in this way can promote
the formation of 4-hydroxynonenal, an endogenous electrophilic activator of
Nrf2 (198). However, untransformed cells, such as the primary fibroblasts used
in the present study, are typically protected from the anticancer effects of
sulforaphane (199).
In conclusion, oxidative stress has been well recognized in aging. While
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oxidative stress can be measured in many ways, my studies focused on
oxidation of the extracellular Eh(Cys/CySS) redox potential. Oxidation of
extracellular Eh(Cys/CySS) has been linked to age-dependent lung matrix
remodeling and changes in the phenotype of lung fibroblasts (156, 157), as well
as phenotypic changes in other cell types (144, 200, 201).

Identification of

Slc7a11 as a critical factor in the regulation of the extracellular redox
environment will undoubtedly lead to novel approaches to understanding the
effects of aging in health and disease.
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CHAPTER III

REDOX STATES OF PROTEIN CYSTEINES IN PATHWAYS OF PROTEIN
TURNOVER AND CYTOSKELETON DYNAMICS ARE CHANGED WITH
AGING AND REVERSED BY SLC7A11 RESTORATION IN MOUSE LUNG
FIBROBLASTS

3.1 Introduction
Aging has been proposed as a consequence of failure of redox networks to
sustain biological functions (202). This redox theory of aging accounts for
several hallmarks of aging, including altered intercellular communication, loss
of proteostasis, epigenetic alterations and mitochondrial dysfunction (27, 202),
because each of these is sensitive to changes in redox state of one or more of
its constituent components. One convenient way to assess changes in systemic
redox states is to measure the redox potential (Eh) of the cysteine/cystine
(Cys/CySS) thiol/disulfide redox couple (Eh(Cys/CySS)). Human plasma
typically has an Eh(Cys/CySS) of about -80 mV, and cells grown in culture
condition their media to this same value (134, 157). As we age, plasma
Eh(Cys/CySS) becomes progressively more oxidized (136), and cultured old
cells condition their media to more oxidized values when compared to young
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cells (157). Thus, aging is associated with a disrupted redox environment and
decreased ability to fight against oxidative stress.
Previous studies showed that the expression of Slc7a11, the light chain of
the CySS transporter system Xc-, was decreased in old mouse lung fibroblasts
compared to that of young fibroblasts, concomitant with oxidation of
extracellular Eh(Cys/CySS) that occurs with age (157, 203). Pharmacological
induction and genetic overexpression of Slc7a11 restored extracellular balance
of the Cys/CySS redox couple and its Eh(Cys/CySS) in a glutathione (GSH)
synthesis-independent manner, confirming Slc7a11 is responsible for
controlling extracellular Eh(Cys/CySS) in primary mouse lung fibroblasts (203).
Previous studies also showed extracellular Eh(Cys/CySS) was associated with
a variety of biological processes and diseases. For example, medium with
oxidized Eh(Cys/CySS) induced the expression of TGF-β and fibronectin and
stimulated the proliferation of mouse lung fibroblasts (156). Oxidized
extracellular

Eh(Cys/CySS)

also

promoted

mitochondrial

thioredoxin-2

oxidation and induced reactive oxygen species (ROS) production in aortic
endothelial cells (67). In C6 glial cells, oxidized Eh(Cys/CySS) increased
phosphorylation of extracellular signal-regulated kinase (ERK) and expression
of nuclear factor-κB (NF-κB) and inducible nitric oxide (iNOS) via activating
metabotropic glutamate receptor 5 (153). Plasma Eh(Cys/CySS) was more
oxidized in patients with chronic obstructive pulmonary disease compared to
that in patients with normal lung function (150). Thus, Slc7a11 has the potential
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to influence important intracellular signaling pathways and biological functions
via controlling the extracellular redox environment.
Once transported into cells by system Xc-, CySS is reduced to Cys, which
is the rate-limiting component for GSH synthesis. GSH and Cys have the
capacity to influence the redox states of individual intracellular proteins.
Proteins contain cysteines that can be reversibly oxidized to disulfides or
sulfenic acids. If a redox-sensitive cysteine is located in a catalytic or allosteric
regulatory site, or a protein-protein or protein-DNA interaction domain, its redox
state can determine the function of that protein. Many protein kinases have
been shown to contain redox-sensitive cysteines. For example, oxidation of
Cys797 to a sulfenic acid in the active site of EGFR increased its tyrosine kinase
activity (204). In contrast, intramolecular disulfide bond between Cys297 and
Cys311 and oxidation of Cys124 to a sulfenic acid inhibited the kinase activity
of Akt2, demonstrating that predicting specific changes of biological function
resulting from alterations in the redox states of cysteines is difficult, thereby
requiring evaluation on a case-by-case basis and requiring experimental
confirmation (205, 206). Furthermore, redox changes can affect structural
proteins that contain redox-reactive thiols. In primary mouse lung fibroblasts,
for example, cadmium exposure induced oxidation of cysteines of actin and
actin-associated cytoskeleton proteins, thus changing actin dynamics via
increasing filamentous actin formation and transporting destrin from cytoplasm
to nucleus (207).
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The large number and wide distribution of protein cysteines increase the
functional flexibility of the proteome and play important roles in signal
transduction, aging and disease (208). Redox proteomics can be used to define
the redox states of all protein cysteines under a given set of conditions. Various
redox proteomics methods have been developed, but they share some
common features. In general, these methods rely on differentially labeling
reduced and oxidized cysteines and separating the 2 forms from each other,
followed by quantification of each form (209). This approach was recently used
to study the change of redox states of proteins in brown adipose tissue of mice
exposed to cold temperature (210). This method has been adapted for labelling
reduced and oxidized cysteines to compare redox states between murine
young and old lung fibroblasts, and old fibroblasts with Slc7a11 overexpression.
Currently, there is no information about how Slc7a11 affects the redox state
and function of the cysteine proteome. Furthermore, how aging changes the
redox state of the cysteine proteome in primary mouse lung fibroblasts is
unknown. This study aims to identify intracellular protein cysteines whose redox
states are age-dependent, and to explore the potential biological functions of
these cysteine-containing proteins. Considering that low Slc7a11 expression in
old fibroblasts is responsible for the change of the extracellular redox
environment with aging, I also aim to explore whether and to what extent
restoration of Slc7a11 expression would reverse the age-dependent changes
of intracellular redox environment and signaling pathways.
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3.2 Materials and methods
3.2.1 Reagents
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Corning
(Manassas, VA) unless otherwise specified.
3.2.2 Culture of primary mouse lung fibroblasts
Primary lung fibroblasts were isolated from young (3 months) or old (24
months) female C57BL/6 mice as described in Chapter 2 (176, 211). Animal
maintenance and procedures of animal experiments were approved by the
Institutional Animal Care and Use Committee of the University of Louisville.
After isolation, fibroblasts were cultured in DMEM supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotic-antimycotic solution in a humidified
incubator with 5% CO2. Fibroblasts between passage numbers 10 and 15 were
used in the experiments.
3.2.3 Preparation of redox media with Eh(Cys/CySS) of 0 mV
0 mV redox media were prepared from adding CySS and Cys to cysteinefree and FBS-free DMEM to reach the final concentrations of 99.75 μM for
CySS and 0.5 μM for Cys. All redox media were freshly prepared and used for
fibroblast incubation immediately.
3.2.4 Overexpression of Slc7a11 expression
Plasmid encoding mouse Slc7a11 was purchased from Origene
Technologies, Inc. (Rockville, MD). Two micrograms of plasmid were used to
overexpress Slc7a11 in lung fibroblasts from old mice via electroporation. The
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program of U-023 on the NucleofectorTM 2b Device (Lonza, Allendale, NJ) and
the protocol of the AmaxaTM Basic NucleofectorTM Kit for Primary Mammalian
Fibroblasts (Lonza, Allendale, NJ) were applied for electroporation. One million
fibroblasts underwent transfection and were seeded in 6-well plates.
Fibroblasts were recovered in antibiotic-free DMEM with 10% FBS. After 24
hours, the media were changed to 0 mV redox media for 4 hours incubation.
Finally, media and cells were collected for measuring extracellular
Eh(Cys/CySS) via HPLC and redox states of cysteine residues of intracellular
proteins, respectively.
3.2.5 Media derivatization and high-performance liquid chromatography (HPLC)
analysis
Detailed procedures were described in Chapter 2 (203). Briefly, media were
transferred to a tube containing the same amount of ice-cold solution consisting
of 10% (w/v) perchloric acid, 0.2 M boric acid and 20 μM γ-glutamyl glutamate
(177). Then, media were derivatized with iodoacetic acid and dansyl chloride
for HPLC analysis (Waters Corporation, Millford, MA) (178). Calculation of
Eh(Cys/CySS) was based on the Nernst equation for pH 7.4: Eh(Cys/CySS) = 250+30*log([CySS]/[Cys]2) (134).
3.2.6 Labeling of reduced and oxidized cysteine residues of intracellular
proteins with different iodoacetyl tandem mass tags (iodoTMTs)
My labeling method was developed based on the isobaric iodoTMTsixplex
reagent. Each iodoTMT label contains a thiolate specific-reactive group for
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labeling reduced thiols, a mass reporter with different numbers of isotope
positions for distinguishing different tags in the mass spectrometry, and a mass
normalizer for balancing the molecular weight. Proteins of fibroblasts in each
well were collected and frozen in 300 μl of 10% trichloroacetic acid (TCA) before
labeling. After thawing, proteins were centrifuged at 16,000 g at 4 °C for 15 min.
The protein pellet was washed with ice-cold acetone. Then, the protein pellet
was dissolved in 200 μl of denaturing buffer consisting of 200 mM Tris, 1 mM
EDTA and 0.1% (w/v) SDS, pH 8.5. Immediately thereafter, 100 μl of dissolved
proteins was added to a tube containing one of six iodoTMT reagents freshly
dissolved in 10 μl methanol and incubated for 1 hour at 37°C. This step labels
the reduced cysteines. Proteins were precipitated once again in TCA and
washed with acetone to remove unincorporated iodoTMT reagent. Proteins
were dissolved in 100 μl of denaturing buffer and 1 μl of 500 mM TCEP was
added to reduce reversibly oxidized protein cysteine residues. The newlyreduced cysteines were then labeled by adding the second iodoTMT label and
incubating for 1 hour at 37 °C. Again, proteins were precipitated with TCA and
washed with acetone to remove unincorporated iodoTMT. Finally, doublelabelled protein pellet was dissolved in 60 μl of denaturing buffer.
3.2.7 Digestion, affinity purification and multiplexed liquid chromatographytandem mass spectrometry (LC-MS/MS)
Detailed procedures were described here according to a previous study
(212). The same amount of labelled proteins from different groups were mixed.
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Then, trypsin was used to digest the proteins at 37 °C overnight. After digestion,
peptides were lyophilized and dissolved in 100 μl of Tris-buffered saline (TBS).
0.2 ml of anti-TMT resin beads (0.4 ml of 50% slurry) was used for enrichment
of the digested peptides. Peptides were incubated with the beads at 4 °C
overnight. Then, the beads were washed 3 times with 200 μl of TBS, followed
by 3 times with 0.2 ml water. Finally, the bound peptides were eluted 3 times
with 0.2 ml elution buffer. The elutes were then desalted with C18 spin column
(Pierce, Rockford, IL), dried by speed vacuum, dissolved in 1% formic acid and
analyzed by multiplexed LC-MS/MS.
3.2.8 Ingenuity Pathway Analysis (IPA)
Redox state of a cysteine residue in a protein was defined as the ratio of its
oxidized form to reduced form. Peptides containing cysteine residues that had
significant change of redox state with aging were selected. Among them, the
redox states of cysteines in a subgroup of peptides were reversed by Slc7a11
overexpression. Proteins containing peptides in this subgroup were used for
IPA (http://www.ingenuity.com) and bioinformatic analyses. IPA predicts
networks, canonical pathways and molecular functions associated with the
input list of genes or proteins (213). Fold-changes of the redox states of
cysteines between old and young fibroblasts for the above subgroup were used
as IPA input. The false discovery rate (FDR) threshold was set at 0.05.
3.2.9 Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analysis
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GO analysis is used for annotating genes and their products from 3
categories, including biological process (BP), molecular function (MF) and
cellular component (CC) (214). KEGG (www.genome.jp/kegg/) is a database
for linking genomic information with functional information to achieve analysis
of functions of genes systematically (215). Online Database for Annotation,
Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) was
used to conduct GO enrichment analysis and KEGG pathway analysis (216).
GO and KEGG terms with a p-value < 0.05 were considered significantly
enriched.
3.2.10 Protein-protein interaction (PPI) network construction
STRING database (http://www.string-db.org/) and Cytoscape 3.6.1
(https://cytoscape.org/) were used to construct PPI network to explore
functional associations between proteins (217, 218). The minimum required
interaction score was medium confidence (≥ 0.4).
3.3 Results
3.3.1 Slc7a11 overexpression corrects extracellular Eh(Cys/CySS) in old
fibroblasts
My goal is to explore how aging affects redox states of intracellular cysteine
residues of proteins, and to examine whether Slc7a11 overexpression in old
cells reverses some, if not all, of those changes. Consistent with the previous
studies in Chapter 2 (157, 203), primary lung fibroblasts from old mice showed
lower Slc7a11 expression and more oxidized extracellular E h(Cys/CySS)
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compared to fibroblasts harvested from young mice (Figure 3.1). Genetic
overexpression of Slc7a11 by plasmid in old fibroblasts successfully restored
Slc7a11 expression and resulted in reduction of extracellular E h(Cys/CySS)
close to the levels seen in young fibroblasts, confirming the cell model for
testing the effects of Slc7a11 on the redox environment had been reproduced
(Figure 3.1).
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Figure 3.1 Overexpression of Slc7a11 restored age-dependent oxidation of
extracellular Eh(Cys/CySS) in old fibroblasts. (a) Slc7a11 mRNA expression
and (b) extracellular Eh(Cys/CySS) were measured as described in materials
and methods. Primary lung fibroblasts from young and old mice were isolated
and old fibroblasts were transfected with Slc7a11-overexpressing plasmid
(pSlc7a11). Fibroblasts were plated, and 24 h later the media were changed to
0 mV redox media for 4 h. Data are expressed as mean ± standard deviation
of 3 independent replicates. *- Indicates p < 0.05.
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3.3.2 Identification of intracellular protein cysteines whose redox states
changed with aging but were restored via Slc7a11 overexpression
After collecting the media for measuring extracellular E h(Cys/CySS), the
cells were processed for intracellular cysteine redox proteomic analysis. Three
different iodoTMT labels were used to label biologically reduced cysteine
residues of proteins in young, old, and old Slc7a11-overexpressing fibroblasts
(Figure 3.2). Next, TCEP was used to reduce reversibly oxidized cysteines,
including disulfides, sulfenic acids, S-glutathionylation and S-nitrosylation.
Then, 3 different tags were used to label those originally oxidized cysteines.
Following digestion and enrichment via iodoTMT-affinity resin, peptides were
analyzed via LC-MS/MS. A representative MS/MS spectrum is shown to
demonstrate identification of peptides and quantification of oxidized and
reduced forms from reporter ions (Figure 3.3).
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Figure 3.2 Schematic flow chart of labeling redox-sensitive cysteines in
peptides from young, old and old Slc7a11-overexpressing primary mouse lung
fibroblasts using iodoTMT reagents. Detailed procedure was described in the
main text.
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Figure 3.3 Representative mass spectrum for determining Cys redox state.
Peptides in the mixed samples were ionized and separated by LC-MS/MS.
Specific Cys-containing peptides were selected after the first mass
spectrometry based on the mass to charge ratio. Those peptides were further
fragmented to smaller ions and detected by the second mass spectrometry as
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shown in the upper panel. The region containing peaks of the reporter ions of
the six iodoTMT labels (m/z 126-131) is shown in the lower panel. The peak
intensity ratios of 129/128, 131/130 or 127/126 were defined as redox states
for young, old or old Slc7a11-overexpressing primary mouse lung fibroblasts,
respectively.
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Over one thousand peptides were identified by mass spectrometry. To
facilitate quantitative comparisons, the redox state of a specific cysteine residue
was represented by the ratio of its oxidized portion to its reduced portion (redox
state of cysteine = oxidized portion / reduced portion). To determine how the
redox states of individual cysteines differed between old and young cells, a
volcano plot representing statistical significance on the y-axis and fold-change
of cysteine redox states on the x-axis was produced (Figure 3.4.a). For each
cysteine residue, change of redox state with aging was represented by foldchange (FC) of redox state in old cells relative to young cells (Old vs. Young FC
= redox state of cysteine in old cells / redox state of cysteine in young cells)
(Figure 3.4.a). Among all cysteines with detectable redox states, 12.6%
(162/1282) peptides contained differentially oxidized cysteines with aging
(above the dashed line representing p-value cutoff of 0.05) (Figure 3.4.a). Of
those, 69% (112/162) were more oxidized in the old cells than in the young cells
(above the dashed line and log2FC(Old/Young) > 0), while 31% (50/162) were
more reduced with aging (above the dashed line and log2FC(Old/Young) < 0)
(Figure 3.4.a).
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Figure 3.4 Volcano plot showing peptides with age-dependent Slc7a11reversible Cys redox states. Each dot represented one Cys-containing peptide.
(a) Proteins were differentially oxidized between old and young fibroblasts. The
peptides above the dashed line were considered to contain cysteines whose
redox states changed in response to aging (age-dependent Cys redox state).
Those peptides belonged to 151 proteins. (b) Cys redox states were reversed
by Slc7a11 overexpression. The proteins containing age-dependent Cys redox
states were selected and plotted. Proteins below the dashed line were
considered to contain Slc7a11-reversible Cys redox states. Altogether, 104
proteins contained 116 cysteines whose redox states were reversed by Slc7a11
overexpression. Three replicates of young, old and old Slc7a11-overexpressing
fibroblasts were used to calculate the p-values.

69

The 162 peptides whose redox states changed with aging belonged to 151
proteins. These 151 proteins were selected to further explore whether their
redox states were reversible via Slc7a11 overexpression. Reversibility of agedependent changes of redox state was assessed by comparing the redox state
in old Slc7a11-overexpressing cells relative to young cells (Old Slc7a11
Overexpression vs. Young FC = redox state of cysteine in old Slc7a11overexpressing cells / redox state of cysteine in young cells) (Figure 3.4.b).
Noticeably, 71.6% (116/162) of age-dependent changes of cysteine redox
states were reversible via Slc7a11 overexpression (below the dashed line)
(Figure 3.4.b). The majority of Slc7a11-dependent redox-sensitive cysteines
(93 of 116, or 80%) were more oxidized in old cells, but a substantial number
(23 of 116, or 20%) were more reduced in old cells. The 116 Slc7a11-dependent
cysteine-containing peptides belonged to 104 distinct proteins, with one protein
containing both oxidized and reduced cysteines. Those 104 proteins
constituted the majority (104 of 151, or 69%) of the age-dependent redoxmodified proteins.
The above observations indicated that decreased expression of Slc7a11
with aging might significantly contribute to the age-dependent global changes
observed in the redox states of the intracellular cysteine proteome in primary
mouse lung fibroblasts. These 104 proteins with Slc7a11-dependent redoxsensitive cysteines were focused on to further explore their potential biological
functions using bioinformatics analyses.
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3.3.3 Ingenuity Pathway Analysis (IPA), Gene Ontology (GO) and pathway
enrichment analyses and protein-protein interaction (PPI) network analysis of
proteins with Slc7a11-reversed redox-sensitive cysteines
IPA showed that the most significantly enriched pathways related to
Slc7a11-dependent redox-sensitive proteins were eukaryotic translation
initiation factor 2 (EIF2) signaling, actin cytoskeleton and integrin-linked kinase
(ILK) signaling, and protein ubiquitination pathway, which represented protein
synthesis, cellular structure and communication, and protein ubiquitinproteasome-mediated degradation, respectively (Table 3.1). Three actinassociated cytoskeleton proteins, TLN1, FLNB and PPP2CA, contained
multiple redox-sensitive cysteines, indicating that actin dynamics and
communication between cell membrane and intracellular cytoskeleton were
prone to age-related oxidative stress and, importantly, that Slc7a11
overexpression restored such redox effects of aging (Table 3.1). Interestingly,
not all cysteine residues became more oxidized with aging. On the contrary,
some became more reduced (Table 3.1), indicating that although aging
promoted overall oxidation of the redox environment, the redox states of distinct
components of the intracellular cysteine proteome were differentially regulated
instead of simply being oxidized. Slc7a11 overexpression not only reduced agedependent oxidation of proteins, but also oxidized age-dependent reduction of
certain proteins, suggesting that Slc7a11 influences the cysteine proteome
indirectly via restoring the global intracellular redox environment rather than
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interacting directly with individual redox-sensitive proteins.
GO is a collection of terms describing gene functions and the relationship
between the terms. It consists of 3 aspects: biological process, molecular
function and cellular component. Consistent with IPA, GO annotation for
biological process revealed that Slc7a11-dependent redox-sensitive proteins
were enriched in cell adhesion, initiation and regulation of protein translation,
organization of actin cytoskeleton and proteolysis (Table 3.2). Other significant
enriched terms related to biological process involved RNA processing, cellular
response to stimuli (e.g. virus) and oxidation-reduction processes (Table 3.2).
Furthermore, Slc7a11 affected the redox states of proteins with molecular
function related to the binding of poly(A) RNA, cellular adhesion-related
cadherin, actin, ATP or other proteins (Table 3.3). Related to the GO cellular
component, enriched items included extracellular exosome, cell-cell adherens
junctions and cytoplasm (Table 3.4). Finally, KEGG pathways were mainly
enriched in carbon metabolism and amino acids biosynthesis, ribosome and
proteasome, tight and adherens junctions, and focal adhesion (Table 3.5).
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Table 3.1. Ingenuity Pathway Analysis (IPA) indicated proteins whose redox
states were restored by Slc7a11 overexpression were enriched in pathways of
protein turnover and cytoskeleton signaling. The top 3 most significant enriched
pathways were protein synthesis pathway, protein ubiquitin-proteasomemediated degradation pathway and actin cytoskeleton signaling / integrin-linked
kinase (ILK) signaling. Some proteins contained more than 1 redox-sensitive
Cys residue. Some Cys residues became more oxidized with aging while others
became more reduced.
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protein degradation pathway
(Proteasome-mediated)

actin cytoskeleton signaling /
ILK signaling

protein synthesis pathway
(EIF2 signaling)

Related IPA pathway

reduced

oxidized

reduced

oxidized

reduced

Change of redox
state
oxidized

protein phosphatase 2 catalytic subunit alpha
actin beta
G protein subunit gamma 12
IQ motif containing GTPase activating protein 1
filamin C
proteasome subunit alpha 6
proteasome 26S subunit, non-ATPase 9
proteasome 26S subunit, non-ATPase 11
proteasome 26S subunit, non-ATPase 13
S-phase kinase associated protein 1
heat shock protein family A (Hsp70) member 9
proteasome subunit beta 1
USO1 vesicle transport factor

ACTB
GNG12
IQGAP1
FLNC
PSMA6
PSMD9
PSMD11
PSMD13
SKP1
HSPA9
PSMB1
USO1

myosin heavy chain 9
talin 1

MYH9
TLN1

PPP2CA

eukaryotic translation initiation factor 2 subunit gamma
actinin alpha 4
ARP3 actin related protein 3 homolog
filamin A

EIF2S3
ACTN4
ACTR3
FLNA

filamin B

GTTEEICQIYLR
IAIWTTECENR
VACIGAWHPAR
TGVACSVSQAQK
IAVHCTVR
GCTATLGNFAK
LNISFPATGCQK
LCYVALDFEQEMATAASSSSLE
K
IVLTNPVCTEVGEK
ACLISLGYDVENDR
YSYVCPDLVK
SNFTVDCSK
CSGPGLSPGMVR
KQELEEICHDLEAR
QVAASTAQLLVACK
CVSCLPGQR
VVAPTISSPVCQEQLVEAGR
AGALQCSPSDVYTK
IAGPGLSSCVR
ACIPQSFTVDSSK
AHQLVMEGYNWCHDR
QITQVYGFYDECLR
LCYVALDFEQEMATAASSSSLE
K
ASADLMSYCEEHAR
FFQVACDVPELQDK
DGSCGVSYVVQEPGDYEVSIK
YGYEIPVDMLCK
GIGMNEPLVDCEGYPR
TTANAIYCPPK
SSDEAVILCK
GLLDVTCK
CELSSSVQTDINLPYLTMDASG
PK
ICIVTK
SQLCSQSLEITR
eukaryotic translation initiation factor 3 subunit C
eukaryotic translation initiation factor 4E
ribosomal protein L3
ribosomal protein L9
ribosomal protein L11
ribosomal protein S2
ribosomal protein S6
actin beta

EIF3C
EIF4E
RPL3
RPL9
RPL11
RPS2
RPS6
ACTB

FLNB

Redox-sensitive Cys

Description

Protein

Table 3.2 GO-based biological process analysis of proteins whose redox states
were rescued by Slc7a11 overexpression in old fibroblasts. Fisher’s exact test
p-values for all the items shown were lower than 0.05.
Term

Count

cell-cell adhesion

11

0.000

7.197

translation

11

0.000

4.274

RNA splicing

8

0.000

3.526

tricarboxylic acid cycle

4

0.000

3.319

platelet aggregation

4

0.001

2.971

mRNA processing

8

0.002

2.786

RNA secondary structure unwinding

4

0.002

2.757

translational initiation

4

0.003

2.529

cellular response to peptide hormone stimulus

3

0.007

2.147

formation of translation preinitiation complex

3

0.008

2.112

establishment or maintenance of cell polarity

3

0.009

2.047

response to virus

4

0.010

1.994

pentose-phosphate shunt, non-oxidative branch

2

0.026

1.581

oxidation-reduction process

9

0.027

1.564

actin cytoskeleton reorganization

3

0.031

1.507

isocitrate metabolic process

2

0.031

1.503

proteolysis involved in cellular protein catabolic process

3

0.037

1.433

positive regulation of translation

3

0.037

1.433

neuron projection development

4

0.038

1.422

actin cytoskeleton organization

4

0.040

1.399
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p-value

-log10 (p-value)

Table 3.3 GO-based molecular function analysis of proteins whose redox states
were rescued by Slc7a11 overexpression in old fibroblasts. Fisher’s exact test
p-values for all the items shown were lower than 0.05.
Term

Count

poly(A) RNA binding

39

0.000

20.191

cadherin binding involved in cell-cell adhesion

20

0.000

15.060

enzyme binding

13

0.000

5.841

actin binding

12

0.000

5.558

actin filament binding

8

0.000

5.054

RNA binding

16

0.000

4.598

protein complex binding

11

0.000

4.521

protein binding

42

0.000

4.517

nucleotide binding

25

0.000

3.935

protein domain specific binding

9

0.000

3.682

GTP binding

9

0.001

2.878

ATP binding

19

0.001

2.826

protein kinase binding

9

0.003

2.540

ATP-dependent RNA helicase activity

4

0.005

2.284

GTPase activity

6

0.006

2.206

oxidoreductase activity

10

0.006

2.191

ADP binding

3

0.017

1.768

Rac GTPase binding

3

0.022

1.662

endopeptidase activity

4

0.025

1.610

nucleoside binding

2

0.027

1.561

76

p-value

-log10 (p-value)

Table 3.4 GO-based cellular component analysis of proteins whose redox
states were rescued by Slc7a11 overexpression in old fibroblasts. Fisher’s
exact test p-values for all the items shown were lower than 0.05.
Term

Count

extracellular exosome

57

0.000

23.688

cell-cell adherens junction

20

0.000

14.949

cytoplasm

72

0.000

14.704

focal adhesion

16

0.000

9.092

myelin sheath

12

0.000

8.558

extracellular matrix

13

0.000

7.639

cytosol

28

0.000

7.085

intracellular ribonucleoprotein complex

12

0.000

6.291

spliceosomal complex

8

0.000

5.304

actin cytoskeleton

9

0.000

5.162

cytoplasmic ribonucleoprotein granule

5

0.000

4.983

cortical cytoskeleton

5

0.000

4.801

stress fiber

6

0.000

4.700

cytoskeleton

18

0.000

4.543

perinuclear region of cytoplasm

14

0.000

4.457

protein complex

13

0.000

4.216

nucleus

49

0.000

4.123

extracellular vesicle

5

0.000

4.002

catalytic step 2 spliceosome

6

0.000

3.947

proteasome complex

5

0.000

3.498

77

p-value

-log10 (p-value)

Table 3.5 KEGG pathway analysis of proteins whose redox states were rescued
by Slc7a11 overexpression in old fibroblasts. Fisher’s exact test p-values for all
the items shown were lower than 0.05.
Term

Count

Carbon metabolism

8

0.000

4.183

Spliceosome

7

0.001

2.972

Tight junction

7

0.001

2.873

Citrate cycle (TCA cycle)

4

0.003

2.569

Salmonella infection

5

0.005

2.317

Proteasome

4

0.007

2.147

Biosynthesis of antibiotics

7

0.011

1.955

Adherens junction

4

0.025

1.597

Biosynthesis of amino acids

4

0.031

1.507

Proteoglycans in cancer

6

0.033

1.484

Focal adhesion

6

0.035

1.453

Ribosome

5

0.039

1.414

78

p-value

-log10 (p-value)

PPI network demonstrates the interactions between proteins in a
straightforward and visualized way. Proteins with functional connections are
clustered. Three clusters were identified from the PPI network (Figure 3.5). The
upper left cluster was associated with cytoskeleton and cellular interaction,
including actin signaling and integrin-linked kinase (ILK) signaling (Figure 3.5).
The upper right cluster was involved in protein translation pathways, including
EIF2 signaling (Figure 3.5). The lower cluster was related to protein
ubiquitination and proteasome-mediated degradation (Figure 3.5). Those data
were consistent with the IPA results and suggested that, by reversing the
intracellular redox environment, Slc7a11 was able to block the age-dependent
changes of redox states of protein cysteines in pathways of cytoskeleton
dynamics and protein turnover.
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Figure 3.5 Protein-protein interaction (PPI) network showed proteins with agedependent Slc7a11-responsive cysteines were clustered in IPA-predicted
pathways. The upper left cluster was associated with cytoskeleton and cellular
interaction, including actin signaling and integrin-linked kinase (ILK) signaling.
The upper right cluster was associated with protein translation, including
eukaryotic translation initiation factor 2 (EIF2) signaling. The lower cluster was
related to protein ubiquitination and degradation. Proteins that contained agedependent oxidized, reduced, or both oxidized and reduced cysteines were
shown in round, triangular or round rectangular boxes, respectively.
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3.4 Discussion
The current study confirms the role of Slc7a11 in mediating age-dependent
oxidization of extracellular Eh(Cys/CySS) and extends these findings to include
the impact of changes in Slc7a11 expression on the redox states of multiple
intracellular proteins. Proteins related to the cytoskeleton or involved in protein
degradation and protein synthesis are differentially oxidized in old murine lung
fibroblasts as a result of lower Slc7a11 expression. Slc7a11 overexpression not
only reduces proteins that become oxidized with aging, but also oxidizes certain
proteins that are reduced with aging. Thus, targeting Slc7a11 for redox
regulation might be a better approach than simply supplementing with
antioxidants to re-establish redox homeostasis in aging and diseases.
The redox states of particular cysteines associated with actin cytoskeleton
signaling and ILK signaling are age-dependent but can be restored with
Slc7a11 overexpression. Integrins mediate cell-cell and cell-matrix interactions,
thereby linking extracellular matrices with the intracellular cytoskeleton. Talin
and alpha-actinin, which are components of focal adhesion complexes (219,
220), are shown in Chapter 3 to contain cysteines whose redox states are
oxidized with aging. These changes might impact integrin-mediated signaling
or mechanotransduction through alterations in cell stiffness, a process
considered critical for promoting aberrant lung remodeling after injury and
fibrosis (221, 222). Others have shown that cytoskeletal proteins are oxidized
with aging. Protein carbonylation is an irreversible oxidative modification that is
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increased in the brains of old senescence-accelerated-prone 8 (SAMP8) mice
compared to the brains of young mice (223). In particular, collapsin response
mediator protein-2 (CRMP-2), which is involved in cytoskeletal remodeling,
microtubule assembly and cell migration, and alpha-spectrin, which interacts
with actin to form a scaffold to maintain cytoskeletal stability and flexibility, are
more oxidized (224). Thus, the actin cytoskeleton system might be a major
target of age-dependent redox modification. S-glutathionylation is a form of
reversible oxidation of cysteines. Actin contains cysteines with different degrees
of S-glutathionylation that are flexibly deglutathionylated via glutaredoxin in
response to stimuli (225). Glutaredoxin-mediated changes of cysteine Sglutathionylation may regulate actin polymerization (226). These findings are
considered important as the actin cytoskeleton is believed to play critical roles
in fibroblast differentiation, myofibroblast contraction, focal adhesion complex
formation, extracellular matrix remodeling, mechanical to biochemical signal
transduction, and gene transcription, which are all important biological
processes proposed to be involved in tissue fibrogenesis and maladaptive
wound healing (227). In human skin fibroblasts, disassembly of actin
cytoskeleton results in disruption of the TGF-β signaling pathway with
subsequent collagen production, thus promoting skin aging (228). These
findings further support the idea that the function of the actin cytoskeleton
system is redox-sensitive, and its disruption might be associated with agingrelated degeneration and disease development.
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Loss of proteostasis is a hallmark of aging (27). Proteostasis (from the
terms protein and homeostasis) refers to the balance among the processes of
protein synthesis, folding, trafficking and degradation. Redox modulation has
been shown to affect protein folding and trafficking (229, 230). Disruption of
proteostasis can result in deposition of protein aggregates and be harmful for
cell survival (231, 232). Protein degradation by the proteasome changes with
aging and is regulated by redox modulation, especially thiol oxidation (233, 234).
Here, three age-oxidized cysteines in proteasome 26S subunit and one agereduced cysteine in heat shock protein 70 (HSP70) were identified, providing
further evidence for the idea that the 26S proteasome is vulnerable to oxidative
stress, and that its chaperone HSP70 responds to redox regulation (235, 236).
The implications of age-dependent changes of protein redox states in the
promotion of aging-associated diseases require further exploration. However,
studies in Chapter 3 suggest that they are important and are in line with other
observations. For instance, in the hippocampi of patients with Alzheimer
disease (AD), peptidyl-prolyl cis-trans isomerase 1 (Pin 1), which catalyzes
isomerization of neuronal cytoskeleton protein tau, becomes more oxidized
(237). Ubiquitin carboxyl terminal hydrolase L-1 (UCHL-1) is involved in
proteasome-mediated protein degradation, and its oxidation in AD disrupts the
ubiquitination/de-ubiquitination balance and results in accumulation of
dysfunctional proteins (237). Furthermore, proteins in the cell structural and
proteasomal pathways are oxidatively modified in Parkinson disease (238).
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Others have identified cysteine redox modifications that affect proteostasis.
For example, S-glutathionylation of multiple cysteine residues results in
increased accessibility of proteasomal active center and increased proteolytic
activity (239). In this chapter, several other novel reversible redox-sensitive
cysteines that might also influence proteasomal activity were identified.
Whether proteosomal activity is increased or decreased depends on both the
location and specific form of the redox modification being evaluated, thereby
requiring experimental exploration in the future. Nevertheless, observations in
Chapter 3 suggest that both cytoskeleton and proteasomal pathways are
susceptible to age-related oxidative stress, and that redox modulations of
cysteines might be an important post-translational mechanism responsible for
age-dependent change of protein functions in those pathways.
Protein synthesis was also found to be disrupted with aging and modified
by Slc7a11-associated change of the redox environment. Compared to
relatively well studied age-dependent protein degradation, how protein
synthesis is altered with aging remains to be explored. My study found that
aging was associated with changes of redox states of cysteines in EIF2
signaling, including EIF4E, RPS6 and RPL9. These three proteins regulate
protein synthesis in aging (240). The concentration and activity of eukaryotic
translation initiation factors (eIFs) and the abundance of ribosomes are
decreased with aging, resulting in an overall decrease in protein synthesis (241).
These and the identification of several other age-dependent cysteines in other
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parts of eIFs and ribosomes suggest that cysteine redox modifications mediate
age-dependent defects detected in the protein synthesis machinery. The
function of eIF2, for instance, is to load methionyl-tRNA to 40S ribosomal
subunit, which is the first step of 43S preinitiation complex assembly (242). The
function of eIF4E is to bind with the 5’ cap of mRNAs and mediate recruitment
and attachment of 43S preinitiation complex (243). Those two steps determine
the rate of protein synthesis. Phosphorylation of those initiation factors and their
regulatory factors have been shown to control protein synthesis (244, 245).
Similar to phosphorylation, redox modifications might represent another posttranslational mechanism capable of affecting the efficacy of protein synthesis.
This idea is further supported by a recent study that revealed several H 2O2sensitive thiols in proteins involved in the general translation machinery, and
the subsequent attenuation of protein synthesis via such redox modulation
(246). More studies are needed to further elucidate this redox control of protein
synthesis pathways.
Perhaps the most important finding of Chapter 3 is that Slc7a11
overexpression may restore the protein redox microenvironments. Accordingly,
one could predict that alterations in Slc7a11 expression or activity would lead
to diseased states. Consistent with this idea, others reported that increase of
Slc7a11 was part of the signatures of senescence inflammatory responses in
intestinal epithelial cells (247). In peripheral white blood cells from
schizophrenia patients, Slc7a11 expression was lower compared to those from
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healthy donors (248). In tissues of non-small cell lung cancer, Slc7a11
expression was higher (249). In glioma cells, the C-terminus of EGFR directly
interacts with the central part of Slc7a11 and stabilizes Slc7a11 cell surface
expression (250), thereby suggesting a role in oncogenic signaling. CD44
variant directly interacts with Slc7a11 in pulmonary artery endothelial cells
suggesting a role in vascular remodeling (251). Those interactions further
complicate the potential biological roles of Slc7a11. It is unclear whether and
how Slc7a11 expression changes in different cell types and whether such
change affect the progression of aging or disease development differently.
Although the upstream or downstream pathways of Slc7a11 might be different,
the universal underlying mechanism is usually associated with Slc7a11-related
change of redox environment, suggesting redox modulation might play a central
role in controlling multiple biological processes and signaling pathways.
Slc7a11 provides cells with Cys to support GSH synthesis. Therefore, one
of the functions of Slc7a11 activity may be to support reduction of oxidized
proteins by providing an essential co-factor for glutaredoxins (94).
Glutaredoxins

preferentially reduce

glutathionylated

proteins,

whereas

thioredoxins more efficiently reduce protein disulfides and sulfenic acids and
are involved in de-nitrosylation of cysteines (87, 252-255). The link between
Slc7a11 activity and thioredoxin-dependent protein reduction is not as direct as
it is for glutathione-dependent processes, but an increase in GSH synthesis
may decrease the overall burden on the thioredoxin system. The results in
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Chapter 3 showed that while most cysteines became more oxidized in lung
fibroblasts from aged mice, some became more reduced, and Slc7a11
overexpression reversed redox states of both oxidized and reduced cysteines,
supporting the idea that Slc7a11 manipulation targets intracellular redox
signaling pathways rather than simply decreases overall oxidative stress. This
might provide novel insight for combatting oxidative stress associated with
aging and age-related aberrant wound healing.
In conclusion, aging is associated with disruption of the intracellular redox
environment represented by changes in the redox states of cysteines in
fundamental pathways including protein turnover and cytoskeleton organization.
Slc7a11 is a critical factor not only for regulating the extracellular redox
environment, but also for controlling the intracellular redox environment.
Targeting Slc7a11 can reverse age-dependent effects of oxidative stress on
intracellular signaling pathways and lead to novel approaches to fighting
against oxidative stress in age-related diseases.
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CHAPTER IV

DECREASED SLC7A11 IS ASSOCIATED WITH OXIDATION OF
EXTRACELLULAR CYSTEINE/CYSTINE REDOX STATE (EH(CYS/CYSS))
IN HUMAN LUNG FIBROBLASTS: A POTENTIAL SUSCEPTIBILITY STATE
FOR IDIOPATHIC PULMONARY FIBROSIS

4.1 Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial
lung disease (256). It is characterized by irreversible destruction of alveoli,
accumulation of aberrant matrix proteins in the lung interstitium, and remodeling
of lung tissue resulting in scarring (257). The main clinical symptoms are dry
cough and worsening shortness of breath, and the physical signs include
bibasilar pulmonary crackles and finger clubbing (3). Oxygen supplementation
is often needed as pulmonary function declines. The burden of IPF is not
negligible. Over 180,000 Americans are currently affected by IPF, and the
incidence as well as prevalence is still increasing worldwide (6, 258). IPF is
insidious and progressive, usually diagnosed at later stages because of its
chronic and non-specific nature. Even though the progression of IPF can be
decelerated by pirfenidone or nintedanib, it’s still lethal because no intervention
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has been proved to halt or reverse the fibrosis (18, 19). Furthermore, IPF mainly
affects people from 55 to 75 years of age. The median age at diagnosis is 66
and the median survival time is 3 to 5 years (12, 259). As the world population
is aging, it is imperative to explore new diagnostic approaches for detecting IPF
during its initial stage or new treatment options capable of reversing the fibrotic
process. Thorough understanding of the mechanisms underlying IPF on the
cellular and molecular levels is fundamental for developing innovative
diagnostic biomarkers and effective treatments.
Lung fibroblasts from IPF patients are different than those from non-IPF
donors. Fibroblasts are the effector cells that produce excessive extracellular
matrix proteins and manifest a fibrotic phenotype in IPF. IPF fibroblasts show
decreased proliferation, decreased telomere length, enlarged morphology,
increased resistance to apoptosis, increased expression of senescent markers
(β- galactosidase, p16, p21, p53), and increased cytokine production
(interleukin-6, interleukin-1β, fibroblast growth factor 2) belonging to the
senescence-associated secretory phenotype (SASP), all of which are
characteristics of cellular senescence (29, 260). Furthermore, media from
senescent fibroblasts stimulate the expression of α-smooth muscle, collagen
and fibronectin in non-senescent fibroblasts, indicating that senescent
fibroblasts are pro-fibrotic and fibroblast senescence might play a key role in
mediating IPF (261).
Redox homeostasis is disrupted in IPF fibroblasts. For example,
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mitochondrial dysfunction has been documented in IPF fibroblasts, including
over-production of reactive oxygen species (ROS), up-regulation of genes
related with mitochondrial synthesis and electron transport chain, increased
mitochondrial DNA content and increased activity of mammalian target of
rapamycin complex 1 (mTORC1), a mitochondrial homoeostasis mediator (111).
IPF fibroblasts also express increased NADPH (reduced nicotinamide adenine
dinucleotide phosphate) oxidase 4 (NOX4) (96). Expression of nuclear factor,
erythroid 2 like 2 (NRF2), a major regulator of multiple anti-oxidant genes, is
absent in fibroblast foci of IPF lung tissue (96). Both mitochondrial dysfunction
and disturbance of the NOX4-NRF2 axis may promote fibroblast senescence
and differentiation into myofibroblast and myofibroblast apoptosis resistance
resulting in increased susceptibility to lung fibrosis after injury (96, 111).
Redox couple together with its redox potential is another type of readily
available biomarker of redox environment. Cysteine (Cys) and its oxidized form,
cystine

(CySS),

constitute

the

major

extracellular

redox

couple.

Glutathione/glutathione disulfide (GSH/GSSG) is the major intracellular redox
couple. Previous studies show extracellular Cys/CySS redox potential
(Eh(Cys/CySS)) is more oxidized for cultures of fibroblasts from old mice
compared to young mice (157). Oxidation of extracellular Eh(Cys/CySS)
promotes pro-fibrotic responses of primary mouse lung fibroblasts, including
activation of TGF-β/Smad signaling and induction of extracellular matrix
proteins, such as fibronectin (156). Plasma Eh(Cys/CySS) and Eh(GSH/GSSG)
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are progressively oxidized with aging in humans (137). Considering aging is the
biggest risk factor for IPF, oxidation of redox couples might potentially mediate
the effects of aging on promoting lung fibrosis. In the bleomycin-induced lung
injury murine model, oxidation of plasma Eh(Cys/CySS) coincides with fibrosis
while oxidation of plasma Eh(GSH/GSSG) precedes the appearance of fibrosis
(57). Follow-up study in the mouse lung fibroblasts demonstrates that solute
carrier family 7 (cationic amino acid transporter, y+ system), member 11
(Slc7a11), the light chain subunit of system Xc- importing CySS and exporting
glutamate, is the critical molecule for controlling extracellular Eh(Cys/CySS)
(203). Lower Slc7a11 correlates with more oxidizing extracellular Eh(Cys/CySS)
(203). The relationship between Slc7a11 and GSH/GSSH redox couple is less
studied. Furthermore, Slc7a11 affects cysteine thiol oxidation status of
intracellular proteins involved in pathways of protein turnover and cytoskeleton
dynamics. These data suggest targeting Slc7a11 might be a candidate for
interfering development of lung fibrosis.
However, there is no study focusing on the role of redox couples and their
redox potentials in IPF fibroblast pathology. Whether solute carrier family 7
member 11 (SLC7A11) has similar regulatory effects on redox environments for
human lung fibroblasts remains to be explored. The purpose of this study is to
characterize extracellular and intracellular redox potentials for lung fibroblasts
from IPF patients and non-IPF donors and to examine SLC7A11 expression
and its relationship with redox couples in human fibroblasts.
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4.2 Materials and methods
4.2.1 Reagents
Reagents used in this paper were all purchased from Sigma-Aldrich (St.
Louis, MO) or Corning (Manassas, VA) unless otherwise specified.
4.2.2 Fibroblast cultures from IPF patients and non-IPF donors
Six lung specimens from explants of 6 IPF patients receiving lung
transplantation in the University of Louisville Hospital were collected and used
for IPF fibroblast isolation. All patients enrolled in this study provided written
consent. This study was approved by University of Louisville Hospital Ethics
Committee. Fresh tissues were transported immediately to the laboratory for
isolating fibroblasts according to procedures described in Chapter 2 (176, 262).
Non-IPF fibroblasts were kindly provided by Dr. Halayko. They were isolated
from uninvolved periphery of 6 lung cancer patients. Those cancer-adjacent
cells were used as controls. These human lung fibroblasts were cultured in
Dulbecco's Modified Essential Medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% antibiotic-antimycotic mixture. Culture dishes were kept in a
humidified incubator at 37 °C with 5% CO2. Fibroblasts with passage numbers
before 10 were used in the experiments. Age and sex data of IPF patients and
non-IPF donors are presented in Table 4.1.
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Table 4.1 Age and sex of IPF patients and non-IPF donors

Patient number
IPF-1613
IPF-1705
IPF-1710
IPF-1713
IPF-1714
IPF-1715
Non-IPF-004
Non-IPF-005
Non-IPF-090
Non-IPF-103
Non-IPF-128
Non-IPF-138

Age
68
65
67
71
62
64
69
64
56
80
57
55
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Sex
Male
Male
Male
Male
Female
Male
Female
Male
Female
Female
Female
Male

4.2.3 0 mV redox media preparation and fibroblast incubation
DMEM without L-methionine, L-cystine and L-glutamine were used as the
base media for preparation of 0 mV redox media. 0 mV media contained 0.2
mM L-methionine, 4 mM L-glutamine, 99.75 μM L-cystine and 0.5 μM Lcysteine. All 0 mV redox media were prepared immediately before media
change. Fibroblasts were incubated with 0 mV redox media for 24 h.
4.2.4 Derivatization of media and analysis of high-performance liquid
chromatography (HPLC)
Conditioned media were combined with the same amount of ice-cold
solution composed of 200 mM boric acid, 10% (w/v) perchloric acid and 20 μM
γ-glutamyl glutamate (177). Iodoacetic acid and dansyl chloride were used to
derivatize the media for HPLC analysis (Waters Corporation, Millford, MA) (134,
178). Calculations of Eh(Cys/CySS) and Eh(GSH/GSSG) are based on the
Nernst equation for pH 7.4: Eh(Cys/CySS) = -250+30*log([CySS]/[Cys]2) and
Eh(GSH/GSSG) = -264+30*log([GSSG]/[GSH]2) (203).
4.2.5 Measurement of SLC7A11, COL1A1 and ACTA2 mRNA level
RNAqueous®-4PCR Kit (Thermo Fisher Scientific, Waltham, MA) was used
for isolating RNA from human lung fibroblasts of 5 IPF patients and 5 non-IPF
donors without 0 mV redox media incubation. Non-IPF-103 and IPF-1714 were
not included due to cell culture issues. SuperScript™ VILO™ Master Mix Kit
(Thermo Fisher Scientific, Waltham, MA) was used to synthesize cDNA. Real-
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time quantitative PCR (qPCR) was conducted to measure SLC7A11, COL1A1,
ACTA2 mRNA and eukaryotic 18S rRNA (18S) expression with TaqMan probes
(TaqMan® Gene Expression Assay Hs00921938_m1, Hs00164004_m1,
Hs00426835_g1 and Hs99999901_s1; Applied Biosystems), according to the
manufacturer’s protocol (TaqMan Universal Master Mix II; Applied Biosystems).
Step One Plus Real Time PCR System (Applied Biosystems) was used for
qPCR. The following cycle parameters were used: 50°C for 2 min, 95°C for
10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Results were
analyzed using Step One Software version 2.3 (Applied Biosystems). The
amplification curve was analyzed by the mathematical equation of the second
derivative, and the amounts of SLC7A11, COL1A1, ACTA2 mRNA expression
were normalized to the housekeeping gene 18S rRNA expression. Relative
change compared to the average of non-IPF fibroblast samples were calculated
for each cell isolate. Finally, relative expression of mRNA was calculated via
using the 2-ΔΔCT method as in Chapter 2.
4.2.6 Statistical analysis
Data were presented as mean ± standard deviation. Significance was
evaluated by unpaired two-tailed t-test. Linear regression was used to assess
the correlation between redox potential and SLC7A11 expression.
4.3 Results
4.3.1 Extracellular Eh(Cys/CySS) for human lung fibroblasts
Primary lung fibroblasts isolated from IPF patients produced more oxidized
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extracellular Eh(Cys/CySS) than fibroblasts from non-IPF controls (Figure
4.1.A). The average extracellular Eh(Cys/CySS) was -37mV for IPF fibroblasts
and -70mV for non-IPF fibroblasts (Figure 4.1.A). Because Eh(Cys/CySS) was
calculated from concentrations of Cys and CySS. I then looked at their
individual concentrations. Data from 6 IPF and 6 non-IPF patients suggested
that the average extracellular Cys concentration was 4 µM lower for IPF
fibroblasts, accounting for this approximately 33 mV oxidation of Eh(Cys/CySS)
(Figure 4.1.B). Such oxidation and the decrease in Cys were consistent with
the previous mouse study that compared to young mice, extracellular
Eh(Cys/CySS) was more oxidized for fibroblasts from aged mice whose
susceptibility to lung fibrosis was also higher (157, 203). There was no
difference of extracellular CySS concentration between IPF and non-IPF
fibroblasts (Figure 4.1.C).
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Figure 4.1 Extracellular Eh(Cys/CySS) became more oxidized for lung
fibroblasts from IPF patients due to lower extracellular Cys concentration. Lung
fibroblasts from uninvolved periphery of lung tissues of 6 lung cancer patients
(non-IPF) and 6 IPF patients were isolated and cultured in DMEM containing
10% fetal bovine serum. When the cultures were 50% confluent, media were
replaced with serum-free media containing 100 µM CySS (0 mV redox media)
for 24 hours. Media were collected to measure concentrations of Cys and CySS.
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Extracellular Eh(Cys/CySS) was calculated using Nernst equation according to
the following formula: Eh(Cys/CySS) = -250 + 30*log([CySS]/[Cys]2). (A)
Extracellular Eh(Cys/CySS) was more oxidized for IPF fibroblasts. (B)
Extracellular Cys concentration was lower for IPF fibroblasts. (C) Extracellular
CySS concentration was not altered for IPF fibroblasts. *- Indicates p-value <
0.05 compared to non-IPF fibroblasts.
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4.3.2 Expressions of SLC7A11 and pro-fibrotic genes for human lung fibroblasts
Consistent with the hypothesis, SLC7A11 expression was 13-fold lower in
IPF fibroblasts, which could account for the oxidation of extracellular
Eh(Cys/CySS) (Figure 4.2). Collagen type I (COL1A1), which is a typical
extracellular matrix protein, and actin α-2, smooth muscle (ACTA2), which
represents differentiation of fibroblasts into the more pro-fibrotic myofibroblasts,
were shown to be higher in IPF fibroblasts (Figure 4.3).
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Figure 4.2 SLC7A11 expression was lower for IPF fibroblasts. *- Indicates pvalue < 0.05 compared to non-IPF fibroblasts.
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Figure 4.3 Expressions of pro-fibrotic genes were higher for IPF fibroblasts. (A)
COL1A1 expression was higher for IPF fibroblasts. (B) ACTA2 expression was
higher for IPF fibroblasts. *- Indicates p-value < 0.05 compared to non-IPF
fibroblasts.
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4.3.3 Intracellular Eh(GSH/GSSG) for human lung fibroblasts
GSH/GSSG is the major intracellular redox couple. A further step was taken
to investigate whether intracellular Eh(GSH/GSSG) was different between IPF
and non-IPF fibroblasts. In contrast to extracellular Eh(Cys/CySS), intracellular
Eh(GSH/GSSG) was not more oxidized in IPF fibroblasts (Figure 4.4).
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Figure 4.4 Intracellular Eh(GSH/GSSG) was not more oxidized for IPF
fibroblasts. After incubation with 0 mV redox media for 24 hours, cells were
collected for measuring intracellular GSH and GSSG concentrations by HPLC.
Intracellular Eh(GSH/GSSG) was calculated based on Nernst equation using
the following formula: Eh(GSH/GSSG) = -264 + 30*log([GSSG]/[GSH]2).
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4.4 Discussion
The increase of a variety of biomarkers of oxidative stress has been
observed in several IPF-derived samples (34, 60). Redox couples, Cys/CySS
and GSH/GSSG, are among the most commonly used markers to indicate
disruptions of redox homeostasis (75, 76, 80, 81). Plasma Eh(Cys/CySS) is
around -80 mV for healthy elderly people (134). There is about 15 mV oxidation
of plasma Eh(Cys/CySS) for the age-matched IPF patients according to
unpublished data in our group. In the current study, the finding was extended
that Eh(Cys/CySS) became more oxidized not only in human plasma, but also
in media of human lung fibroblast cultures. Furthermore, decreased Slc7a11
expression has been shown to be associated with more oxidized extracellular
Eh(Cys/CySS) in mouse lung fibroblasts in Chapter 2. This correlation was also
observed in human lung fibroblasts in this Chapter. IPF fibroblasts expressed
lower SLC7A11 and their extracellular Eh(Cys/CySS) was more oxidized.
Previous studies also showed media with oxidized Eh(Cys/CySS) increased
pro-fibrotic gene expression in primary mouse lung fibroblasts (156). The profibrotic effect of oxidation of extracellular Eh(Cys/CySS) was confirmed in
human fibroblasts in this chapter. Two representative fibrotic genes, COL1A1
and ACTA2, were shown to be upregulated in IPF fibroblasts. In other words,
SLC7A11-dependent reduction of extracellular Eh(Cys/CySS) in human
fibroblasts was associated with lower pro-fibrotic gene expression, decreasing
the susceptibility of fibrosis. Those data indicate that SLC7A11 might be a
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potential anti-fibrotic target for intervening redox environments before IPF
development and during IPF pathogenesis. Manipulating SLC7A11 might be
effective in preventing and treating IPF.
Regulation of intracellular Eh(GSH/GSSG) was independent of SLC7A11.
Though SLC7A11 was lower in IPF fibroblast, intracellular Eh(GSH/GSSG) was
not different between IPF and non-IPF fibroblasts. This is consistent with the
finding that genetic manipulations of Slc7a11 in mouse lung fibroblasts had no
effect on intracellular Eh(GSH/GSSG) in Chapter 2. It was not surprising that
regulation of extracellular Eh(Cys/CySS) and intracellular Eh(GSH/GSSG) were
mediated via different mechanisms. In fact, this is a good example to show
oxidative stress was not simply overall imbalance between oxidants and antioxidants but disruption of redox regulation network which contains components
that are controlled independently of each other.
The regulatory role of SLC7A11 on redox environments is dependent on
the transporting activity of system Xc-. Exploration of why SLC7A11 was lower
in IPF fibroblast and the relation between SLC7A11 expression and system Xcactivity is critical for understanding the pathogenesis of IPF. Studies of
regulation of SLC7A11 expression and system Xc- activity are primarily focused
on the transcription level and support the idea that transcriptional regulation of
SLC7A11 is much more important for determining system Xc- activity compared
to expression of SLC7A11-interacting heavy chain SLC3A2, which forms
multiple transporting systems with different subunits and lacks specificity (263).
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Transcriptional up-regulation of SLC7A11 has been shown to be mediated
via 3 transcription factors, nuclear factor, erythroid 2 like 2 (NRF2), activating
transcription factor 4 (ATF4) and ETS proto-oncogene 1, transcription factor
(ETS-1) (264-266). NRF2 is a master switch for inducing expressions of
multiple anti-oxidant genes. Not only SLC7A11, but also GSH metabolismassociated genes, inducing glutamate-cysteine ligase (GCL), glutathione
synthetase (GSS), glutathione S-transferase (GST), glutathione peroxidase
(GPX), are all induced when NRF2 binds with the anti-oxidant response
element (ARE) in the corresponding gene promoter in cell nuclei (267, 268).
Without cellular stress, NRF2 is ubiquitinated via kelch like ECH associated
protein 1/cullin 3/ring-box 1 (KEAP1/CUL3/RBX1) E3-ubiquitin ligase complex
and degraded via proteasome (269). ROS, electrophiles and heavy metals
have been shown to up-regulate SLC7A11 via disrupting the inhibitory effect of
KEAP1 on NRF2 and promoting translocation of NRF2 into the nuclei (270,
271). ATF4 mediates SLC7A11 induction via nutrient deficiency (272). Amino
acid deprivation, such as CySS starvation, results in increased number of
unloaded t-RNAs (273). Free t-RNAs then activates general control nonderepressible 2 (GCN2), which is a kinase that phosphorylates eukaryotic
translation initiation factor 2α (eIF2α) (274). Phosphorylation of eIF2α further
promotes translation of ATF4, and ATF4 promotes SLC7A11 transcription via
binding to the amino acid response element (AARE) in SLC7A11 promoter
region (275). Furthermore, ETS proto-oncogene 1, transcription factor (ETS-1),
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downstream of RAS, increases SLC7A11 expression in synergy with ATF4,
suggesting the supportive role of SLC7A11 in RAS-induced tumorigenesis
(266).
Other transcription factors can down-regulate SLC7A11 transcription,
including p53, ATF3, BTB and CNC homology 1 (BACH1) and POU class 2
homeobox 1 (POU2F1) (276-279). The p53 protein is a famous tumor
suppressor that regulates genes associated with cell cycle arrest, apoptosis
and senescence (280). Though p53 inhibits SLC7A11 transcription, mutation of
p53 does not always accompany over-expression of SLC7A11 in multiple
tumors, further supporting the idea that transcription of SLC7A11 is regulated
by multiple mechanisms (249, 276, 281). SLC7A11 is closely associated with
ferroptosis, a non-apoptotic and iron-dependent form of regulated cell death
resulted from GSH exhaustion and lipid peroxides accumulation (282). ATF3,
which is induced by various cellular stresses including DNA damage and
oxidative stress, decreases SLC7A11 transcription in a p53-independent way
and promotes erastin-induced ferroptosis (277, 283, 284). BACH1 competes
with NRF2 for ARE in promoters of redox associated genes (285). Contrary to
NRF2, BACH1 suppresses expressions of those anti-oxidant genes including
SLC7A11, stimulating ferroptosis (279, 286). POU2F1 also binds with SLC7A11
promoter region and inhibits SLC7A11 transcription, resulting in change of
melanin production of melanocytes and change of fur color in rabbits (278).
Deubiquitinases involved in chromatin modification have been shown to
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inhibit SLC7A11 transcription. BRCA1-associated protein 1 (BAP1) is a tumor
suppressor and inhibits SLC7A11 expression via decreasing H2A ubiquitination
(287, 288). Under ferroptotic stress, p53 binds with ubiquitin-specific peptidase
7 (USP7) and promotes USP7 translocation into the nuclei, where USP7
inactivates SLC7A11 transcription via removing monoubiquitination of histone
H2B at lysine 120 (H2Bub1) (289). This inhibitory effect of p53 on SLC7A11
expression via epigenetic chromatin regulation is independent of its inhibitory
effect as a transcription factor (289).
Chromatin remodeling molecules also influence SLC7A11 transcription.
SWI/SNF chromatin-remodeling complex is altered in many cancers (290). ATrich interaction domain 1A (ARID1A) gene encodes one component of this
complex (291). It enhances the effect of NRF2 on inducing SLC7A11 (292).
ARID1A deficiency impairs NRF2 recruitment and NRF-mediated SLC7A11
transcription (292). However, over-expression of NRF2 rescues SLC7A11
expression, indicating ARID1A is not essential for SLC7A11 induction (292).
MicroRNAs (miRNAs) bind with and suppress SLC7A11 mRNA. MiR-26b,
miR-27a, miR‑126‑3p, miR‑126‑5p, miR-372, miR-373, miR-374b-5p, miR-375,
miR-627-5p, miR-3683, miR-4669 and miR-4740-3p have all been shown to
target 3’-untranslated region (3’-UTR) of SLC7A11 transcripts to inhibit
SLC7A11 mRNA translation or to promote SLC7A11 mRNA degradation (293301).
A variety of endogenous cytokines and exogenous stimulants, such as
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interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), fibroblasts growth factor
2 (FGF2), erythropoietin (EPO) and bacterial lipopolysaccharide (LPS),
increases SLC7A11 transcription (195). However, the mechanisms are not
elucidated.
Interactions between SLC7A11 protein and other molecules can increase
or decrease the activity of system Xc-., depending on the interactive molecules.
EGFR physically interacts with and stabilizes SLC7A11 protein in a kinaseindependent manner in EGFR-expressing glioma cells, which manifest
increased CySS uptake and enhanced anti-oxidant capacity (250). CD44 is an
adhesion molecule (302). Variant isoform of CD44 (CD44v) is expressed in
epithelial tumors (303). CD44v interacts with and stabilizes SLC7A11,
maintaining higher intracellular GSH synthesis for survival of gastrointestinal
cancer cells (304). CD44v-SLC7A11 interaction is also involved in acquisition
of cisplatin-resistance in lung cancer and 5-fluorouracil-resistance in gastric
cancer (305, 306). CD133, a cancer stem cell marker, is shown to stabilize
SLC7A11 and increase survival and drug resistance of liver cancer cells (307).
The stability of SLC7A11 also requires the heavy chain SLC3A2 (308). On the
contrary, formation of SLC7A11-Beclin 1 (BECN1) complex inhibits system Xcactivity (309, 310). BECN1 is a key component in the stage of nucleation during
autophagy (311). Sulfasalazine and erastin induce phosphorylation and
activation of AMP-activated protein kinase (AMPK) (309). AMPK further
phosphorylates BECN1 (309). Phosphorylated BECN1 interacts with SLC7A11
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protein directly, resulting in suppression of system Xc- activity (309). Inhibition
of system Xc- activity via formation of BECN1-SLC7A11 complex has also been
shown to mediate isoflurane-induced toxicity (310).
Post-translational modifications of SLC7A11 also change the activity of
system Xc-. OTU deubiquitinase, ubiquitin aldehyde binding 1 (OTUB1) directly
interacts with SLC7A11 and stabilizes SLC7A11 via deuibiquitination (312).
Furthermore, this OTUB1-SLC7A11 interaction is enhanced via overexpression
of CD44 (312). On the contrary, mTORC2 interacts with and phosphorylates
SLC7A11, resulting in inhibition of system Xc- activity (313).
Methylation of SLC7A11 DNA is shown to be inversely correlated with
alcohol consumption in a study using saliva samples from European American
males and another study using blood samples from non-Hispanic white females
(314, 315).
Whether expression and stability of SLC7A11 are regulated via these or
other mechanisms and how activity of system Xc- change correspondingly
remain to be explored in IPF and non-IPF human fibroblasts.
In conclusion, lung fibroblasts from IPF patients have more oxidized
extracellular Eh(Cys/CySS) than lung fibroblasts from non-IPF donors. Lower
SLC7A11 could account for the oxidation of extracellular Eh(Cys/CySS) and
subsequent increase of pro-fibrotic genes in IPF fibroblasts. Future studies will
explore how SLC7A11 is dysregulated in IPF fibroblasts to identify new
therapeutic targets for preventing and reversing lung fibrosis.
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CHAPTER V

SUMMARY AND DISCUSSION

5.1 Slc7a11 and its role in regulating redox environments for lung fibroblasts
Because of the earlier emergence of oxidation of redox potentials
compared to clinical symptoms and the pro-fibrotic effects of such oxidation, it
is imperative to explore how redox potential is regulated and whether oxidation
could be intervened and reversed. Previous studies have shown Slc7a11 is a
candidate for controlling redox potentials.
Aging is associated with oxidation of redox potentials. Plasma
Eh(Cys/CySS) becomes progressively oxidized at a linear rate of 0.16 mV/year
over the entire age span (136, 137). Plasma Eh(GSH/GSSG) is stable before
45 years old, but gets oxidized at a faster rate of 0.7 mV/year after 45 years old
(136, 137). Lung fibroblasts isolated from old mice produce a more oxidizing
extracellular Eh(Cys/CySS) than fibroblasts from young mice, which reproduces
age-dependent oxidation of redox environment observed in human plasma
(157). Furthermore, the capacity to recover from oxidative challenge is
decreased in old fibroblasts as it takes longer time to re-establish the set-point
value of extracellular Eh(Cys/CySS) for those old fibroblasts (157). Therefore,
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those primary lung fibroblasts from young and old mice provide us with a good
in vitro model to explore the regulation of redox potentials.
Concomitant with oxidation of extracellular Eh(Cys/CySS), the expression
of Slc7a11 is 10-fold lower in old fibroblasts than young fibroblasts (157).
Slc7a11 is the substrate-specific part of system Xc-, a CySS/glutamate
antiporter located on cell membrane (172, 316). System Xc- is a heterodimer
and composed of the light chain Slc7a11 and the heavy chain Slc3a2 (317).
The ratio of system Xc--mediated CySS import and glutamate export is 1:1 (318).
Slc7a11 determines the specific function and activity of system Xc- (195, 319).
Slc3a2 is also known as CD98 or 4F2 heavy chain and is responsible for
trafficking of Slc7a11 to the cell membrane as a chaperone (320, 321). Slc3a2
also interacts with other light chains to form other amino acid transporters (322324). Therefore, Slc7a11 plays a more important role in studying regulation of
system Xc- activity.
Slc7a11 connects the Cys/CySS and GSH/GSSG redox couples (Figure
5.1). After CySS is imported via Slc7a11, it is reduced rapidly to Cys
enzymatically by thioredoxin reductase 1 (Txnrd1) or thioredoxin domain
containing 17 (Txndc17) or non-enzymatically by GSH because of the much
more reducing intracellular environment compared to the extracellular
environment (186, 195). Cys produced from Slc7a11-mediated CySS import is
the major source of cellular Cys, although in several tissues, Cys can be
synthesized from homocysteine or methionine via transsulfuration pathway

112

(325, 326). Cys can be exported by system ASC directly and oxidized back to
CySS (327). Cys is also the rate limiting component for intracellular GSH
synthesis (188). Glutamate-cysteine ligase (GCL) catalyzes the combination of
Cys and glutamate to form γ-glutamyl cysteine, and glutathione synthetase
(GSS) further catalyzes the addition of glycine to γ-glutamyl cysteine to
generate GSH (175). GSH is the major small molecular anti-oxidant inside the
cells. It reduces various oxidants with or without enzymes, mitigating oxidative
stress. GSSG is the oxidative product formed from two molecules of GSH linked
by a disulfide. GSSG can be reduced back to GSH by glutathione reductase
with electrons from NADPH (328). Both GSH and GSSG can be exported by
the multi-drug resistance protein (MRP) (329-331). Outside of the cells,
membrane-bound γ-glutamyl transferase (GGT) breaks down GSH to release
glutamate and cysteinyl glycine (332). Dipeptidase then cleaves cysteinyl
glycine to produce Cys and glycine (332). Though other transporters are
present, Slc7a11-dependent transporting system Xc- is pivotal for the
maintenance of the cycle between Cys/CySS and GSH/GSSG.
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Figure 5.1 Connection between Cys/CySS and GSH/GSSG redox couples.
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The biological roles of Slc7a11 are based on system Xc--mediated CySS
import and could be mediated by system Xc--related Cys release. It has been
observed that age-dependent oxidation of extracellular Eh(Cys/CySS)
coincides with age-dependent decrease of Slc7a11 in primary lung fibroblasts,
suggesting the potential regulatory role of Slc7a11 on redox potentials (157).
Chapter 2 shows Slc7a11 is the key controller of extracellular Eh(Cys/CySS)
(203). Furthermore, induction or over-expression of Slc7a11 correlates with
increase of extracellular Cys concentration, while suppression or knock-down
of Slc7a11 correlates with decrease of extracellular Cys concentration (203).
Extracellular CySS concentration does not change significantly after Slc7a11
manipulation (203). Those results show although Slc7a11 imports CySS directly,
it is the exported Cys that mediates the regulatory effect of Slc7a11 on
extracellular Eh(Cys/CySS). Blocking intracellular GSH synthesis results in
dramatic depletion of extracellular GSH concentration without affecting
extracellular Cys concentration, indicating GSH synthesis and export might not
be essential for regulation of extracellular Eh(Cys/CySS) (203). In support of my
observations, another study also shows that system Xc--mediated CySS uptake
drives Cys release in both vascular smooth muscle cells and endothelial cells
(333). Rather than the increased intracellular GSH, the reducing extracellular
environment created by system Xc--associated Cys release increases
lymphoma cell survival (190). Change of extracellular Eh(Cys/CySS) itself also
has multiple biological influences, which has been discussed in previous
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paragraphs in Section 1.3. Taken together, one possible mechanism by which
Slc7a11 exerts its functions could be directly linked to regulation of Cys/CySS
balance and its redox potential without requiring the interaction between
Cys/CySS and GSH/GSSG redox couples.
Slc7a11 regulates intracellular redox environments in a GSH-dependent
manner, and the effects can also be reflected by multiple peptidyl cysteines.
Cysteines are widely distributed among proteins and could be important sites
for post-translational modifications (334, 335). Cys can be in the reduced form
or a variety of oxidized forms (336). Some of the oxidize forms are reversible
(e.g. disulfide, sulfinic acid) while some are not (e.g. sulfonic acid) (163). Some
thiols exist in the active thiolate form with negative charge while some are not
based on local pH (208). Cys can also form coordination compounds with
transition metal ions (337). The structural diversity of Cys results in the
functional flexibility. Redox state of a specific peptidyl Cys is quantitatively
represented by the ratio of the oxidized portion to the reduced portion of this
Cys. The results in Chapter 3 show redox states of Cys change spontaneously
with aging. Though oxidative stress increases with aging, redox states do not
become oxidized for all Cys residues, indicating that in addition to the general
oxidation of intracellular redox environment, specific pathways are regulated
individually via redox regulation. Slc7a11 decreases aging (157, 203).
Considering Cys reduced from system Xc--imported CySS provides the ratelimiting component for GSH synthesis, decrease of Slc7a11 level could result
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in decrease of intracellular GSH level, disrupting the balance of intracellular
redox environments and redox signaling. Many studies have confirmed
decrease or Slc7a11 expression or inhibition of system Xc- activity results in
decrease of GSH, rendering cells more susceptible to death (338-340).
However, the downstream effects on redox states of Cys and redox signaling
are less studied. My studies fill the gap and indicate that over-expression of
Slc7a11 might compensate for its age-dependent deficiency and re-establish
the optimal homeostasis of redox environments. Furthermore, restoration of
intracellular redox environment further results in reverse of Cys redox states
and redox signaling, at least partially. In Chapter 3, I have found the most
affected age-dependent Slc7a11-responsive signaling pathways are eukaryotic
translation initiation factor 2 (EIF2) signaling, actin cytoskeleton and integrinlinked kinase (ILK) signaling and protein ubiquitination pathway. These 3
pathways demonstrate that peptidyl Cys residues whose redox states change
with aging but are reversible by Slc7a11 over-expression are enriched in basic
biological activities including protein turnover and cytoskeleton dynamics.
Mechanisms responsible for regulating redox environments are altered
during IPF pathogenesis. Chapter 4 shows human lung fibroblasts from IPF
patients produce a more oxidizing extracellular Eh(Cys/CySS) than fibroblasts
from non-IPF donors. This is consistent with my observation that plasma
Eh(Cys/CySS) of IPF patients is more oxidized than that of non-IPF donors.
Considering Slc7a11 is the key regulator of extracellular E h(Cys/CySS) in
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primary mouse lung fibroblasts, I hypothesize Slc7a11 could have similar roles
in human lung fibroblasts. However, higher Slc7a11 expression only correlates
with more reduced extracellular Eh(Cys/CySS) in non-IPF fibroblasts, while this
correlation is impaired in IPF fibroblasts. Furthermore, the correlation between
Slc7a11 expression and intracellular Eh(GSH/GSSG) in non-IPF fibroblasts is
also disrupted in IPF fibroblasts. Those results indicate Slc7a11 might lose its
role of mediating the cycle between Cys/CySS and GSH/GSSG redox couples
during IPF development.
5.2 Strengths and weaknesses
Studies in this dissertation focus on regulation of both extracellular and
intracellular redox environments by fibroblasts. The interaction between
fibroblasts and redox environments are comparable to that between fibroblasts
and matrix proteins. Oxidation of extracellular environments stimulates profibrotic responses of fibroblasts while fibroblasts are able to regulate their redox
environments. However, the regulatory capability was impaired with aging, the
most important risk factor of IPF, and altered during IPF fibrogenesis. Change
of redox environments could occur even before the appearance of irreversible
fibrosis, indicating potential clinical significance for early intervention to halt or
even reverse fibrosis. My model of lung fibroblasts from young and old mice
simulates the effects of aging in vitro and allows us to explore why the ability of
maintaining optimal redox environments is decreased with aging and what is
the key controller of redox environments for fibroblasts. The young and old
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fibroblasts were isolated from healthy mice. The studies in this dissertation tried
to uncover how the susceptibility increases before the actual fibrosis happens.
Thus, it is the initial step towards finding novel targets for early intervention to
decrease IPF susceptibility. This dissertation also begins to examine whether
mouse and human fibroblasts share similar regulatory mechanisms of redox
environments and compare IPF and non-IPF fibroblasts. This is the further step
towards revealing whether actual redox environments and their regulatory
mechanisms are altered in the diseased status of IPF. This is the foundation of
developing targets for future clinical trials.
There are several limitations. First, fibroblasts are not the only cells involved
in IPF pathogenesis. Epithelial cells, inflammatory cells, endothelial cells and
pericytes might all have different and complementary roles to play. Their exact
contributions to IPF are not fully elucidated. Whether and how those cell types
contribute to regulation of redox environments and whether there are
interactions between fibroblasts and other cell types remain unexplored.
Second, the discrepancies of redox regulation mechanism between IPF and
non-IPF fibroblasts could be attributed to the small sample size. Fibroblasts
from only 6 IPF patients and 6 non-IPF donors are available. It is unknown
whether adding more samples will change the conclusion. Last, confirmation of
the changes of redox states of peptidyl cysteines in the age-dependent
Slc7a11-responsive pathways are needed as redox proteomic assays are not
as accurate as individual experiments targeting specific proteins.
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5.3 Future directions
5.3.1 What is the role of Slc7a11 in mediating the anti-fibrotic effects of
sulforaphane in bleomycin-induced lung fibrosis mouse model?
This dissertation focuses on exploring the role of Slc7a11 in regulating
extracellular and intracellular redox environments mouse and human lung
fibroblasts in vitro. In vivo experiments using wild-type and Slc7a11 knock-out
mice will further clarify the role of Slc7a11. Sulforaphane is used in Chapter 2
to induce Slc7a11 expression. Sulforaphane has also been shown to decrease
mRNA expression of pro-fibrotic genes and deposition of collagen, mitigating
bleomycin-induced lung fibrosis in mice (341). It will be interesting to explore
whether Slc7a11 mediates these anti-fibrotic effects of sulforaphane.
5.3.2 How expression of Slc7a11 is regulated with chronological aging?
Chapter 2 shows Slc7a11 expression is lower in fibroblasts isolated from
old mice compared to young mice. Why aging results in decrease of Slc7a11
remains to be explored. Chapter 4 includes summaries of transcriptional and
post-transcriptional regulation of Slc7a11 expression and post-translational
regulation of Slc7a11 activity. Whether those mechanisms are responsible for
the age-dependent decrease of Slc7a11 in primary mouse lung fibroblasts and
whether there are other mechanisms involved remain to be explored.
5.3.3 Is there a connection between cellular senescence and Slc7a11
expression? How do they relate to each other?
Fibroblasts isolated from IPF patients display multiple characteristics of
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cellular senescence (29). Chapter 3 shows Slc7a11 restores age-dependent
changes of redox potentials of many proteins. It will be interesting to explore
whether Slc7a11 manipulations could reverse changes of senescent markers.
If Slc7a11 could indeed affect the process of aging, it will be of great value to
study how such effect is connected to the susceptibility of IPF.
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LIST OF ABBREVIATIONS
α-SMA

Alpha-smooth muscle actin

AARE

Amino acid response element

ACTA2

Actin α-2, smooth muscle

AD

Alzheimer disease

AEC

Alveolar epithelial cell

Akt2

Serine/threonine kinase 2

AMPK

AMP-activated protein kinase

ARE

Anti-oxidant response element

ARID1A

AT-rich interaction domain 1A

ATF4

Activating transcription factor 4

BACH1

BTB and CNC homology 1

BAL

Bronchoalveolar lavage

BAP1

BRCA1-associated protein 1

BECN1

Beclin 1

BP

Biological process

BSO

Buthionine sulfoximine

CAT

Catalase

CC

Cellular component

CD44

Cluster of differentiation 44
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CD44v

Variant isoform of CD44

CO2

Carbon dioxide

COL1A1

Collagen type I

COPD

Chronic obstructive pulmonary disease

CREB

cAMP response element binding protein

CRMP-2

Collapsin response mediator protein-2

CUL3

Cullin 3

Cys

Cysteine

CySS

Cystine

DAVID

Database for Annotation, Visualization and Integrated
Discovery

DMEM

Dulbecco's Modified Essential Medium

EBC

Exhaled breath condensate

ECM

Extracellular matrix

EDTA

Ethylenediaminetetraacetic acid

EGFR

Epidermal growth factor receptor

Eh

Redox potential

EIF2

Eukaryotic translation initiation factor 2

eIF2α

Eukaryotic translation initiation factor 2α

EIF4E

Eukaryotic translation initiation factor 4E

ELF

Epithelial lining fluid

EMT

Epithelial-to-mesenchymal transition
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EPO

Erythropoietin

ERK

Extracellular signal-regulated kinase

ETS-1

ETS proto-oncogene 1, transcription factor

FBS

Fetal bovine serum

FDR

False discovery rate

FGF2

Fibroblasts growth factor 2

FLNB

Filamin B

GCL

Glutamate-cysteine ligase

GCLC

Catalytic subunit of glutamate-cysteine ligase

GCLM

Modifier subunit of glutamate-cysteine ligase

GCN2

General control non-derepressible 2

GGT

Gamma-glutamyl transferase

GO

Gene Ontology

GPX

Glutathione peroxidase

GRX

Glutaredoxin

GSH

Glutathione

GSS

Glutathione synthetase

GSSG

Glutathione disulfide

GST

Glutathione S-transferase

H2O

Water

H2O2

Hydrogen peroxide

HIV

Human immunodeficiency virus
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HPLC

High-performance liquid chromatography

HRCT

High-resolution computed tomography

HSP70

Heat shock protein 70

ICAT

Isotope-coded affinity tag

IL-1β

Interleukin-1β

ILK

Integrin-linked kinase

iNOS

Inducible nitric oxide synthase

IodoTMT

Iodoacetyl tandem mass tag

IPA

Ingenuity Pathway Analysis

IPF

Idiopathic pulmonary fibrosis

KEAP1

Kelch like ECH associated protein 1

KEGG

Kyoto Encyclopedia of Genes and Genomes

LAP

Latency-associated protein

LC-MS/MS

Liquid chromatography-tandem mass spectrometry

LPS

Lipopolysaccharide

LTBP

Latent TGF-β binding protein

MAPK

Mitogen-activated protein kinase

MDA

Malondialdehyde

MF

Molecular function

mGlu5

Metabotropic glutamate receptor 5

miRNA

MicroRNA

MMP

Matrix metallopeptidase
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MRP

Multi-drug resistance protein

mTORC1

Mammalian target of rapamycin complex 1

NAC

N-acetylcysteine

NADH

Reduced nicotinamide adenine dinucleotide

NADPH

Reduced nicotinamide adenine dinucleotide phosphate

NF-κB

Nuclear factor-κB

NOX

NADPH oxidase

NRF2

Nuclear factor, erythroid 2 like 2

O2

Oxygen

O2-

Superoxide anion

OTUB1

OTU deubiquitinase, ubiquitin aldehyde binding 1

PBS

Phosphate-buffered saline

PCA

Perchloric acid

Pin 1

Peptidyl-prolyl cis-trans isomerase 1

POU2F1

POU class 2 homeobox 1

PPI

Protein-protein interaction

PPP2CA

Protein phosphatase 2 catalytic subunit alpha

PRX

Peroxiredoxin

qPCR

Quantitative PCR

RBX1

Ring-box 1

Redox

Reduction and oxidation

ROH

Alcohol
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ROOH

Organic hydroperoxide

ROS

Reactive oxygen species

RPL9

Ribosomal protein L9

RPS6

Ribosomal protein S6

SAMP8

Senescence-accelerated mouse-prone 8

SASP

Senescence-associated secretory phenotype

SDS

Sodium dodecyl sulfate

Slc7a11

Solute carrier family 7, member 11

SOD

Superoxide dismutase

SRX

Sulfiredoxin

System ASC System alanine-serine-cysteine
TBS

Tris-buffered saline

TCA

Trichloroacetic acid

TCEP

Tris(2-carboxyethyl)phosphine

TEAC

Trolox equivalent anti-oxidant capacity

TGF-β

Transforming growth factor-β

TLN1

Talin 1

TNFα

Tumor necrosis factor α

TRX

Thioredoxin

Txndc17

Thioredoxin domain containing 17

Txnrd1

Thioredoxin reductase 1

UCHL-1

Ubiquitin carboxyl terminal hydrolase L-1
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UIP

Usual interstitial pneumonia

USP7

Ubiquitin-specific peptidase 7

3’-UTR

3’-untranslated region

4F2hc

4F2 heavy chain

8-OHdG

8-hydroxy-deoxyguanosine
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